

Sertm2 is a conserved micropeptide that promotes GDNF-mediated motor neuron subtype specification

Fang-Yu Hsu ^{1,2}, Ya-Ping Yen ¹, Hung-Chi Fan ¹, Mien Chang¹ & Jun-An Chen ^{1,2,3}✉

Abstract

Small open-reading frame-encoded micropeptides within long noncoding RNAs (lncRNAs) are often overlooked due to their small size and low abundance. However, emerging evidence links these micropeptides to various biological pathways, though their roles in neural development and neurodegeneration remain unclear. Here, we investigate the function of murine micropeptide *Sertm2*, encoded by the lncRNA *A730046J19Rik*, during spinal motor neuron (MN) development. *Sertm2* is predicted to be a conserved transmembrane protein found in both mouse and human, with subcellular analysis revealing that it is enriched in the cytoplasm and neurites. By generating C terminally Flag-tagged *Sertm2* and expressing it from the *A730046J19Rik* locus, we demonstrate that the *Sertm2* micropeptide localizes in spinal MNs in mice. The GDNF signaling-induced *Etv4*⁺ motor pool is impaired in *Sertm2* knockout mice, which display motor nerve arborization defects that culminate in impaired motor coordination and muscle weakness. Similarly, human *SERTM2* knockout iPSC-derived MNs also display reduced *ETV4*⁺ motor pools, highlighting that *Sertm2* is a novel, evolutionarily conserved micropeptide essential for maintaining GDNF-induced MN subtype identity.

Keywords Motor Neurons; Long Noncoding RNA; Micropeptide; *Etv4*; GDNF

Subject Categories Neuroscience; RNA Biology

<https://doi.org/10.1038/s44319-025-00400-0>

Received 22 August 2024; Revised 4 February 2025;

Accepted 7 February 2025

Published online: 19 March 2025

See also: [M Lisi et al](#)

Introduction

Long noncoding RNAs (lncRNAs) are a class of RNA transcripts that exceed 500 nucleotides in length and have traditionally been considered as non-protein-coding (Mattick et al, 2023). However, recent findings indicate that small open-reading frames (sORFs) embedded within these lncRNAs may be translated into functional small proteins, termed micropeptides (Magny et al, 2013; Matsumoto et al, 2017). These micropeptides have likely been overlooked due to genome annotation conventions that set an

arbitrary 300-nucleotide (100-codon) threshold for defining coding potential. Moreover, advances in computational and experimental approaches have revealed that a significantly larger proportion of the genome is actively translated than previously recognized (Makarewich and Olson, 2017; Yeasmin et al, 2018). Thus, sORFs that encode evolutionarily conserved micropeptides have been identified within transcripts originally classified as ‘non-coding’. These micropeptides have been proven to exert critical roles in various biological processes, functioning both independently and as regulators of larger proteins (Makarewich, 2020). Emerging research now indicates that micropeptides play essential roles in fundamental biological processes, including myoblast fusion, calcium homeostasis, and cardiomyocyte biology (Hassel et al, 2023). These findings on sORF-encoded polypeptides (SEPs) open up new avenues for research into their regulatory potential in cellular and developmental biology (Saghatelian and Couso, 2015). For example, Myoregulin (MLN), a conserved 46-amino-acid micropeptide, was initially classified as a product of an lncRNA. MLN is expressed across all three types of skeletal muscle and interacts with sarcoplasmic reticulum (SR) Ca^{2+} -ATPase (SERCA), a membrane pump critical for regulating SR Ca^{2+} uptake. By inhibiting Ca^{2+} uptake into the SR, MLN complexes promote muscle relaxation (Anderson et al, 2015). Another micropeptide originating from an lncRNA is PAR-amplifying and CtIP-maintaining micropeptide (PACMP), a 44-amino-acid peptide highly enriched in breast tumors. PACMP appears to play a role in cancer progression and drug resistance by modulating the DNA damage response, highlighting its therapeutic potential in cancer treatment (Zhang et al, 2022). While biological roles have been confirmed for only a small number of the micropeptides identified to date, this rapidly expanding field highlights the substantial work that remains to fully understand their existence and functions. In particular, the roles of micropeptides during neural development remain largely unclear. This topic is particularly intriguing given that lncRNAs are predominantly expressed in the mammalian nervous system (Briggs et al, 2015; Chen and Chen, 2020), and many neuropeptides, some of which are small secretory peptides, play a crucial role in neuronal physiology (Liau et al, 2023). A recent study discovered that *MALAT1*, traditionally regarded as a nuclear lncRNA, may be exported into the cytoplasm in differentiating neurons and produce a micropeptide, M1. Synaptic stimulation was shown to enhance M1 expression, indicating that *MALAT1* could function as a cytoplasmic coding RNA that modulates

¹Institute of Molecular Biology, Academia Sinica, Taipei 11529, Taiwan. ²Genome and Systems Biology Degree Program, Academia Sinica and National Taiwan University, Taipei 10617, Taiwan. ³Neuroscience Program of Academia Sinica, Academia Sinica, Taipei, Taiwan. ✉E-mail: jac2210@gate.sinica.edu.tw

synaptic activity, opening up a new avenue for investigating the roles of micropeptides in neural tissues (Xiao et al, 2024).

To further explore this topic, we use spinal motor neurons (MNs) as a model to systematically investigate MN differentiation and specification and to test if any MN-derived lncRNAs might have the potential to produce functional micropeptides and thereby act in the MN generation process. Motor neuron development is driven by a well-defined set of spatiotemporal transcription factors (TFs). Specifically, MN differentiation is largely regulated by extrinsic signals that control intrinsic genetic programs, which define and stabilize MN subtype identities, particularly those within MN columns and pools. This organization is most evident at the limb level, where MNs that supply limb muscles located in the lateral motor column (LMC) are subdivided into molecularly distinct motor pools, each innervating specific muscle groups (Chen and Chen, 2019; Dasen and Jessell, 2009). The diversification of MN subtypes is primarily governed by the Hox family of homeodomain-containing TFs (Miller and Dasen, 2024). These factors act in a combinatorial manner, regulating the rostrocaudal expression of *Foxp1*, a key determinant of LMC MNs in the brachial and lumbar spinal cord (Dasen et al, 2008).

Within the LMC, distinct MN pools are defined by specific TFs, such as the ETS transcription factors *Etv4* (*Pea3*) and *Etv1* (*Er81*) (Arber et al, 2000; Catela et al, 2016; Ladle and Frank, 2002), the runt-related protein *Runx1*, and the Pou-domain transcription factor *Pou3f1* (*Scip*) (Dasen et al, 2005; Helmbacher et al, 2003). The role of Hox TFs in fine-tuning MN pool differentiation has been studied extensively using selective MN pool markers. Functional experiments altering *Hox* gene expression in MN pools have revealed corresponding changes in MN pool markers, with the outcomes closely linked to modifications in motor axon trajectories toward their muscle targets (Stifani, 2014). *Etv4* and *Etv1* are expressed in specific MN pools in the vertebrate spinal cord, and limb ablation in early chick embryos eliminates their expression (Lin et al, 1998). In this context, glial cell line-derived neurotrophic factor (GDNF) has been identified as one of the major limb-producing signals that induces the *Etv4*⁺ motor pool subsets in the LMC (Haase et al, 2002; Lin et al, 1998; Livet et al, 2002). Striking alterations in MN positioning, muscle target invasion, dendritic development, and sensory-motor connectivity have been observed in *Etv4* mutant mice (Vrieseling and Arber, 2006). These findings underscore the significant role of both early intrinsic transcriptional programs and target-derived signals in MN differentiation. However, the mechanistic link between how target-dependent GDNF signaling integrates with the early-established Hox transcriptional networks in MNs remains to be elucidated. Furthermore, how retrograde GDNF signaling impacts specific *Etv4*-mediated molecular targets to ensure sensory-motor connectivity also needs to be scrutinized.

In this study, we have identified a highly MN-enriched lncRNA *A730046J19Rik* (4.7 kb) that contains a conserved sORF of 270 base pairs encoding an 89-amino-acid micropeptide, *Sertm2* (serine-rich and transmembrane domain containing 2). Strikingly, we demonstrate that *Sertm2* is strongly expressed in the *Etv4*⁺ motor pools. Furthermore, we have discovered that mouse *Sertm2* may modulate peripheral GDNF signaling. Mice lacking *A730046J19Rik* containing *Sertm2* exhibit defects in axonal arborization, particularly in the *Etv4*⁺ motor pools targeting the cutaneous maximus and anterior latissimus dorsi muscles, resulting in impaired walking

coordination and motor function. Moreover, loss of the *Etv4*⁺ motor pools caused by *A730046J19Rik* deletion could be rescued by administering the micropeptide *Sertm2*. In line with these observations, depletion of human *SERTM2* significantly impairs *ETV4* expression, underscoring the critical role of *Sertm2* in MN development in both mice and humans. Our study identifies a functional, conserved lncRNA-derived micropeptide in spinal MNs, establishing a foundation for future research into the roles of micropeptides in neural development and neurodegeneration.

Results

Identification of a motor neuron-enriched lncRNA, *A730046J19Rik*

In a previous effort to uncover novel lncRNAs potentially critical for MN development, we differentiated *Mnx1::GFP* embryonic stem cells (ESCs) into spinal MNs or non-MNs according to established protocols (Fig. 1A). We compared MN progenitors (pMNs, Day 4) with nascent differentiated MNs (*Mnx1::GFP^{on}* cells) sorted from embryoid bodies, as well as dissociated MNs displaying neurite outgrowth at Day 7. Among the identified lncRNA candidates, *A730046J19Rik* was prominent as not only does it exhibit MN-specific expression (Fig. 1B,C) (Yen et al, 2018), but it is also highly conserved across mammals (Fig. EV1A). In line with our finding, a previous study also found that *A730046J19Rik* is enriched in differentiated MNs (Biscarini et al, 2018). Subsequent quantitative polymerase chain reaction (qPCR) analysis confirmed *A730046J19Rik* expression in spinal MNs, with peak levels observed between postnatal day 1 (P1) and P7 (Fig. 1D). Next, we performed in situ hybridization (ISH) on embryonic spinal cords from embryonic day 9.5 (E9.5) to P14 and found that *A730046J19Rik* primarily localizes at the ventral marginal zone of the spinal cord (Fig. 1E). In E13.5 brachial spinal cord sections, *A730046J19Rik* appeared to be enriched in specific MN subtypes, particularly in *Foxp1*⁺ LMC MNs, which innervate limb muscles, and in *Lhx3*⁺ medial motor column (MMC) MNs that innervate epaxial muscles (Fig. 1F).

To gain a finer resolution of the MN subtypes associated with *A730046J19Rik* during mouse spinal cord development, we analyzed its expression using our previously generated single-cell RNA-sequencing (scRNA-seq) dataset on E13.5 *Mnx1::GFP* mouse spinal MNs (Liau et al, 2023). Based on molecular signatures of known columnar markers in brachial MNs, we observed that *A730046J19Rik* is differentially expressed in both MMC MNs and LMC MNs (Figs. 1G and EV1B). Notably, *A730046J19Rik* was expressed in three major MMC MN subtypes (*Nr2f2*, *Satb2*, and *Bcl11b*; Fig. EV1B), but it was highly co-expressed with *Etv4* in *Etv4*⁺ (*Pea3*⁺) motor pools and displayed clear segregation from *Pou3f1*⁺ (*Scip*⁺) populations in the LMC MN subtypes (Figs. 1G,H and EV1D). This expression pattern was further validated using RNAscope-based in situ hybridization, whereby *A730046J19Rik* was examined alongside the MMC-specific markers *Satb2* and *Nr2f2* (Fig. EV1C), as well as the LMC markers *Etv4* and *Pou3f1* (Fig. 1I,J). Co-localization of *A730046J19Rik* and *Etv4* expression, with clear segregation from that of *Pou3f1*, in the brachial region implies a potential role for *A730046J19Rik* in modulating *Etv4*-associated motor functions. Collectively, these findings indicate that *A730046J19Rik* is exclusively expressed in postmitotic MNs and may












Figure 1. Spatiotemporal dynamics of *A730046J19Rik* expression during MN development.

(A) Illustration showing the timeline of motor neurons (MNs) derived from *Mnx1::GFP* mouse embryonic stem cells (ESCs). RA retinoic acid, SAG smoothed agonist, pMNs motor neuron progenitors, MNs motor neurons. (B) Heatmap showing the gene expression profiling of protein-coding genes [pink] and lncRNAs [blue] during mouse ESC-derived MN differentiation. The green color gradient indicates the stage specificity score across stages from ESCs to MNs or non-MNs. The strand-specific RNA-seq data analyzed in this figure was sourced from Yen et al, 2018. (C) qPCR analyses showing the expression of *A730046J19Rik* during mouse ESC-derived MN differentiation. Data are presented as fold change (FC) relative to MNs at Day 7 with values representing the mean \pm SD from $n = 3$ independent experiments and analyzed using ordinary one-way ANOVA. $P < 0.001$ ($P = 2.75 \times 10^{-9}$ for MNs vs. ESC; $P = 4.04 \times 10^{-9}$ for MNs vs. pMNs; $P = 4.8 \times 10^{-8}$ for MNs vs. postmitotic MNs; $P = 3.52 \times 10^{-9}$ for MNs vs. non-MNs). (D) qPCR analyses showing the expression of *A730046J19Rik* in B6 mouse spinal cord at various developmental stages. Data are presented as fold change (FC) relative to the expression at E12.5, with values representing the mean \pm SD from $n = 4-7$ independent spinal cord samples, as indicated in the figure. (E) In situ hybridization (ISH) shows that *A730046J19Rik* expression is gradually enriched and restricted to the ventral horn of the developing spinal cord. Scale bars: 50 μ m (E9.5), 100 μ m (E13.5 and P14). (F) A high-magnification image of *A730046J19Rik* ISH and adjacent immunostaining sections from E13.5 brachial spinal cord demonstrating that *A730046J19Rik* expression is enriched in columnar MN subtypes, as revealed by *Foxp1* and *Lhx3* staining. Dashed lines outline the spinal cord boundary. Scale bars, 50 μ m. (G) (Left) Uniform Manifold Approximation and Projection (UMAP) plot of 16 LMC subclusters from single-cell RNA sequencing (scRNA-seq) of *Mnx1::GFP* labeled-MNs in E13.5 brachial spinal cord (Rostral C4-T3 segments). The four shaded colors represent distinct subtypes within limb MNs, including rLMCl (rostral lateral, orange), rLMCm (rostral medial, green), cLMCl (caudal lateral, blue), and cLMCm (caudal medial, pink) regions. (Right) UMAP plots displaying the expression patterns of *A730046J19Rik*, *Etv4* (*Pea3*), *Pou3f1* (*Scip*), and *Isl1* in LMC MN subtypes. The green gradient represents the expression levels of the genes of interest. The dataset is derived from Liao et al, 2023. (H) Violin plots reflecting the expression of selected genes (*A730046J19Rik*, *Etv4*, *Pou3f1*, and *Isl1*) within LMC MN clusters. The x-axis represents 16 LMC subclusters, categorized as follows: rl (rostral lateral), rm (rostral medial), cl (caudal lateral), and cm (caudal medial). (I, J) RNAscope-based ISH shows the differential subtype distributions of *A730046J19Rik* transcripts among brachial LMC neurons expressing *Etv4* (I) or *Pou3f1* (J) at transcript level at E13.5. Dashed lines outline the spinal cord boundary. Scale bars, 50 μ m.

play a critical role in regulating MN subtype specification, particularly in *Etv4*⁺ motor pools.

A730046J19Rik* encodes a conserved micropeptide, *Sertm2

Although most lncRNAs exhibit low conservation relative to protein-coding genes, accumulating evidence has demonstrated that certain lncRNAs contain conserved sORFs across species (Galindo et al, 2007; Patraquim et al, 2022; Pueyo et al, 2016; Ulitsky, 2016). Notably, the human ortholog of murine *A730046J19Rik*, i.e., *LINC00890*, has been re-annotated as encoding the micropeptide SERTM2 (serine-rich and transmembrane domain containing 2) based on peptidomics data (Fig. EV1E, LncPep) (Liu et al, 2022). To determine if murine *A730046J19Rik* also has the potential to produce a micropeptide, we examined its evolutionary conservation. Using the UCSC Genome Browser, we conducted sequence alignments across multiple species. Homologs of *A730046J19Rik* were identified in several mammals, with a specific region demonstrating significant conservation among vertebrates, though a respective homolog is absent from fish, as revealed by a 100-way Multiz vertebrate alignment using the human genome as the reference. Notably, one highly conserved region within *A730046J19Rik* spans a 270-bp sORF, potentially encoding an 89-amino-acid micropeptide, annotated as *Sertm2* (Fig. 2A). Further alignment of the predicted protein sequence across species highlighted a conserved transmembrane domain (Fig. 2B).

As most lncRNAs tend to be enriched in the nucleus, we reasoned that if *A730046J19Rik* displays coding potential, it should have a cytoplasmic distribution. To explore the subcellular distribution of *A730046J19Rik* in murine MNs, we harvested ESC-derived MNs on Day 7 and performed single-molecule RNA fluorescence in situ hybridization (smFISH). Quantifications revealed that *A730046J19Rik* is more enriched in the cytoplasm than nuclei (Fig. 2C,D). Additionally, computational tools, including PhyloCSF and the Coding Potential Assessment Tool (CPAT), predicted high coding potential for both mouse *A730046J19Rik* and

human *SERTM2* (Figs. EV1F and EV2A) (Lin et al, 2011; Wang et al, 2013). Moreover, a publicly available ribosome profiling database, combined with mRNA abundance coverage from the GWIPS-viz browser, demonstrated significant translational activity within the sORF region of *A730046J19Rik* (Fig. EV2B) (Michel et al, 2014). To experimentally confirm the translation potential of *Sertm2*, we engineered a construct in which ORF was fused to a C-terminal Flag epitope tag. As a negative control, we also mutated the start codon (ATG \rightarrow ATT) of ORF to prevent translation. Following overexpression of both constructs in HEK293T cells, western blot analysis revealed that *Sertm2* encodes a ~17 kDa protein (Fig. 2E,F). Furthermore, immunostaining with an anti-Flag antibody detected the Flag-tagged ORF in the cytoplasmic region and extracellular surface of the HEK293T cells, consistent with predictions that *Sertm2* might be a transmembrane protein (as supported by predictions from Phobius and AlphaFold) (Figs. 2G and EV2C,D) (Jumper et al, 2021). Thus, we re-annotated the original lncRNA *A730046J19Rik* to *Sertm2* given its conserved micropeptide coding potential.

***Sertm2* is generated in mouse spinal cords**

These promising in vitro findings prompted us to examine if *Sertm2* is produced endogenously in the mouse spinal cord. Initially, we raised polyclonal antibodies in both rabbit and guinea pig that target two distinct regions of the *Sertm2* protein (Fig. EV2E). However, western blot and immunostaining assays revealed that both antibodies demonstrated nonspecific. This result was not unexpected, as previous studies have encountered similar challenges in developing antibodies for small proteins of low abundance and limited epitope availability for custom antibody generation (Hassel et al, 2023). To overcome this obstacle, we generated knock-in (KI) mice in which a 3X-Flag tag was inserted at the C-terminus of *Sertm2* (*Sertm2*-Flag KI) (Choi et al, 2023; Ferrando et al, 2015) (Figs. 3A and EV2F,G). Successful tagging of the *Sertm2* transcript with the Flag epitope was confirmed by qPCR, which exclusively detected the Flag sequence in the spinal cord of KI mice, which was absent from control mice (Fig. 3B,C). Utilizing




Figure 2. A730046J19Rik encodes a transmembrane micropeptide, Sertm2.

(A) Comparative sequence analysis illustrating the conservation of *A730046J19Rik* across species. The UCSC Conservation track (Cons 100 Verts) shows conservation scores across 100 vertebrate species, highlighting a highly conserved small open-reading frame (sORF, 270 bp) within exon 3 of the *A730046J19Rik* locus. UTR, untranslated region. (B) Amino acid sequence alignment of the sORFs from the indicated species. The transmembrane domain is highlighted within a colored square. The symbols below the alignment represent sequence similarity: asterisks (*) denote identical residues across all sequences, colons (:) indicate conserved substitutions, and periods (.) suggest similar conservation. (C, D) Single-molecule FISH (smFISH) experiments on mouse *Mnx1::GFP* ESC-derived MNs reveal the localization patterns of *A730046J19Rik* transcripts. A representative image is shown in (C). MNs were identified by the endogenous fluorescent *Mnx1::GFP* signal, and DAPI staining labels the nucleus. Scale bar, 20 μ m. Additionally, quantitative measurements of *A730046J19Rik* expression across different subcellular compartments are shown in (D). Each dot represents one experimental batch, with results presented as mean \pm SD from $n = 5$ independent experiments; unpaired two-tailed t test. $P < 0.001$ ($P = 5.35 \times 10^{-8}$ for Cytoplasm vs. Nucleus). (E–G) The most conserved sORF of *A730046J19Rik* was engineered with a C-terminal Flag tag (ORF-Flag). In parallel, the start codon (ATG) was mutated to ATT to prevent translation, serving as a negative control (Δ ORF-Flag). HEK293T cells were transiently transfected with these constructs and analyzed by immunoblotting (F) and immunostaining (G). Flag detection confirms sORF translation, with *Gapdh* as an internal control in (F). Immunostaining (G) shows that the translated sORF is enriched in the cytoplasm, with DAPI labeling the nucleus. Scale bar, 50 μ m.

the *Sertm2*-Flag KI mice, we employed a mouse monoclonal anti-Flag antibody to detect the endogenous *Sertm2* protein. Western blotting of various tissues from KI mice revealed that *Sertm2* is predominantly enriched in the spinal cord and muscle tissue (Fig. 3D). Interestingly, we found that the detected size of *Sertm2* protein in vitro and in vivo did not correspond to the predicted size of ~ 10 kDa (Figs. 2F and 3C), implying potential post-translational modifications (PTMs). To investigate this possibility, we examined the UniProt database (Fig. EV2H) and used prediction tools such as FindMod to identify potential PTMs in *Sertm2*. Our analysis revealed a predicted glycosylation site. Strikingly, by using PNGase F treatments to deglycosylate the protein, the molecular weight of *Sertm2* more closely matched the predicted value (Fig. EV2I), indicating that *Sertm2* is a glycosylated micropeptide. Moreover, immunostaining at high magnification further demonstrated that *Sertm2* expression is largely localized to the cytoplasmic region of ChAT⁺ MNs in the spinal cord at P7 (Fig. 3E). These findings confirm the spatial expression pattern of *Sertm2* and its presence in spinal MNs, supporting its physiological relevance.

Next, the enrichment of *Sertm2* in muscle tissues prompted us to investigate if the unusually long untranslated regions (UTRs) of *Sertm2* might facilitate its transport along axons. In support of this hypothesis, we identified numerous AU-rich elements (AREs) in the 3' UTR of *Sertm2*, which are known to promote mRNA trafficking within axons (Fig. 3F) (Hong and Jeong, 2023; Loedige et al, 2023). To explore this outcome further, we generated *Sertm2*-Flag KI ESCs and differentiated them into MNs with long axons. Remarkably, we observed an abundant distribution of the *Sertm2* transcript within the MN axons (Fig. EV2J). Given that *Sertm2* was highly co-expressed with *Etv4* motor pools that are induced by peripheral glial cell line-derived neurotrophic factor (GDNF) signaling from muscles (Haase et al, 2002), we further tested if GDNF can affect *Sertm2* distributions. Strikingly, upon addition of GDNF, levels of the *Sertm2* protein were significantly upregulated in the MN axons, indicating that the *Sertm2* micropeptide might be produced in response to GDNF signaling (Fig. 3G). Based on these results, we postulate that *Sertm2* is a GDNF-induced micropeptide in spinal MNs.

***Sertm2* impairment leads to a reduction in *Etv4*⁺ motor pools**

To explore the potential functions of *Sertm2* in differentiated MNs, we utilized a CRISPR/Cas9 approach to delete the entire *Sertm2*

locus in mouse ESCs (Fig. 4A), enabling us to analyze the resulting phenotypes during MN differentiation (Fig. 4B). Successful deletion of the *Sertm2* locus was confirmed by DNA sequencing (Fig. EV3A,B), and absence of its encoded transcript was further verified through qPCR (Fig. 4C). Furthermore, expression of two genes neighboring *Sertm2*, i.e., *Dcx* and *Alg13*, remained unchanged, indicating that *Sertm2* exerts no obvious *cis*-regulatory role (Fig. EV3C,D). Unlike the regular MN differentiation protocols we have adopted previously (Chen et al, 2023; Tung et al, 2015; Tung et al, 2019), we supplemented GDNF following dissociation, as *Etv4* expression is driven by peripheral GDNF signaling (Dasen et al, 2005; Haase et al, 2002). Doing so allowed us to investigate if *Etv4* expression is affected by *Sertm2* deletion. Under these conditions, we observed comparable gene expression of *Mnx1*⁺ cells between *Sertm2* knockout (KO) MNs and control (Ctrl) MNs (wild-type ESC line) (Fig. 4D). Whereas GDNF significantly induced *Etv4* expression in the Ctrl MNs, *Etv4* expression was notably reduced in the *Sertm2* KO ESC-derived MNs (Fig. 4F). Interestingly, expression of the upstream regulator *Hoxc8* remained unchanged, indicating that *Sertm2* exerts a specific role in regulating *Etv4* pool identity through GDNF signaling (Fig. 4E). These findings prompted us to investigate the function of *Sertm2* further by generating *Sertm2* knockout mice. Consistent with our results from ESC-derived MNs, we found that deletion of *Sertm2* did not impact the generation of motor neuron progenitors (Olig2⁺) or generic MNs (Isl1/2⁺ and *Mnx1*⁺) (Fig. EV3E). Furthermore, *Sertm2* knockout did not significantly affect the development of most columnar MMC (Lhx3⁺) and LMC (Foxp1⁺) neurons (Fig. 4G). The MMC subtypes in the spinal cord of *Sertm2* mutant mice showed no significant alterations (Fig. EV3F,G). However, the *Etv4*⁺ motor neuron pools were drastically reduced among Foxp1⁺ MNs, including both the Isl1⁺ pools, which innervate the cutaneous maximus (CM) muscle, and the Isl1⁻ pools that innervate the latissimus dorsi (LD) muscle (Fig. 4H–L). Taken together, our in vitro differentiation and in vivo embryo analyses indicate that the primary function of *Sertm2* in spinal MNs is to specify *Etv4*⁺ MN populations through peripheral GDNF signaling.

Loss of *Sertm2* prompts *Etv4*⁺ motor nerve erosion and a coordinated motor deficit

To investigate further the impact of *Sertm2* loss-of-function on *Etv4* expression within the LMC population in vivo, we analyzed the motor axon trajectory patterns of the *Etv4*⁺ motor pool at E13.5





Figure 3. Endogenous expression and function of *Sertm2*.

(A) Schematic of the genome engineered for CRISPR/HDR-mediated knock-in (KI) of a sequence encoding a C-terminal 3X-Flag tag into the sORF region (light red rectangle) of the *A730046J19Rik* locus in a C57BL/6 (B6) mouse model. The 3X-Flag tag is highlighted in pale purple. HDR, Homology-directed Repair. Genotyping or qPCR primers for [ORF-KI] amplify the ORF-3X-Flag fusion region, spanning the light red to pale purple regions. (B) Verification of Flag insertion in *Sertm2* by qPCR analysis using various primer pairs targeting specific regions. The x-axis indicates primers specific to regions within *A730046J19Rik* or *Sertm2-Flag* KI. Data are presented as fold change (FC) relative to the control expression level and are shown as mean \pm SD, with $n = 4$ independent biological samples per group. The primers for each group are shown in (A) and Fig. 4A. Normalization: [UTR] expression in KI samples was normalized to control [UTR], while [ORF] and [ORF-KI] expression were normalized to control [ORF]. Statistical analysis was conducted using multiple unpaired *t* tests. *P* values for UTR, ORF, and ORF-KI (Ctrl vs. KI) were 0.28, 0.58, and 0.006, respectively. (C, D) Immunoblot analysis of *Sertm2-Flag* in the P7 spinal cord of B6 and *Sertm2-Flag* KI mice (C). Characterization of *Sertm2-Flag* protein expression in various tissues from P7 *Sertm2-Flag* KI mice (D). Anti-Flag detects the *Sertm2* endogenous protein. Gapdh was used as a loading control. (E) Immunostaining for Flag in the P7 *Sertm2-Flag* KI brachial spinal cord reveals enrichment in neurons labeled with ChAT and NeuN. Nuclei are highlighted by DAPI staining. Scale bar, 20 μ m. (F) Scatter plot showing the number of AREs in the 3' UTRs of the indicated genes. Known neurite-localized (red) and soma-localized (blue) genes are plotted. AREs, AU-rich elements. The data was derived from Loedige et al, 2023. (G) Representative images showing the distribution of Flag-tagged *Sertm2* protein in the axons of Ctrl; *Mnx1::GFP* and KI; *Mnx1::GFP* mouse ESC-derived MNs, with varying levels of GDNF supplementation. The Flag tag indicates *Sertm2* protein expression, with motor neuron axons labeled by endogenous *Mnx1::GFP* and nuclei highlighted by DAPI staining. Scale bar, 10 μ m.

by crossing *Sertm2* KO mice with the *Mnx1::GFP* reporter line (Chang et al, 2021; Chen et al, 2023). Examination of the forelimb nerves innervating the CM and LD muscles—located in the subcutaneous tissues of the trunk and back, respectively—revealed significant motor axon arborization defects in the *Sertm2* mutant mice (Fig. 5). Specifically, we observed reduced nerve branching in the LD muscle and diminished coverage in the CM muscle

(Fig. 5A,B). We reasoned that impaired specification of the *Etv4*⁺ motor pool and erosion of the associated motor nerves could elicit deficits in motor coordination, particularly affecting delicate, limb-driven behaviors. Accordingly, we assessed basal motor activity and locomotor coordination in control and mutant mouse lines by means of rotarod, beam walking, grip strength, and treadmill tests. In line with our predictions, *Sertm2* KO mice at approximately P30



exhibited a significant increase in slippage rate during the beam walking test (Figs. 5C,D and EV4A; Movie EV1). To further assess fine motor skills, we employed a treadmill to examine the detailed kinematics of limb coordination and gait patterns (Chang et al, 2021). Remarkably, we observed widespread motor skill impairments across the *Sertm2* KO mice (Fig. 5E–G; Movie EV2 and see Methods for details). Phase analyses of interlimb coordination revealed that although homolateral limb and synchronous diagonal limb gaits—indicative of spinal interneuron circuit integrity—were unaffected, alternating homologous gaits that reflect spinal motor neuron output were significantly compromised in our *Sertm2* KO mice (Fig. 5H,I). These findings indicate that the ventral motor circuitry is disrupted in the absence of *Sertm2*. Moreover, these

coordination deficits persisted into adulthood (P90–120) (Fig. EV4B,C). Collectively, these results underscore the indispensable role of *Sertm2* in maintaining the proper physiological function of the *Etv4*⁺ motor pool.

***Sertm2* administration rescues *Etv4* downregulation in mouse *Sertm2* KO ESC-derived MNs**

To investigate further if the *Sertm2* micropeptide, or its encoding *Sertm2* RNA, regulates *Etv4* expression during MN differentiation, we used CRISPR/Cas9 to delete a 10-bp region from the middle of the *Sertm2* micropeptide in a mouse ESC line (frameshift, FS) (Figs. 6A and EV5A). This approach allowed us to confirm that the

Figure 4. Corroborating the MN phenotype elicited by *Sertm2* knockout.

(A) Generation of the *Sertm2* knockout (KO) mouse cell line and mice using CRISPR/Cas9 gene editing. The paired sgRNAs targeted the entire *Sertm2* locus (dashed rectangle) on the X chromosome. Primers designed for genotyping and qPCR analyses are indicated in the figure. qPCR primers for [UTR] amplify the region spanning exon 2 to exon 3, and [ORF] primers target the sORF region. (B) Experimental timeline for cultured mouse control (Ctrl) and KO ESC-derived MNs, incubated with or without GDNF. (C–E) qPCR analyses of *Sertm2*, *Mnx1*, and *Hoxc8* expression at Day 7 in Ctrl and *Sertm2* KO ESC-derived MNs cultured without GDNF. Data are presented as fold change (FC) relative to Ctrl and shown as mean \pm SD from $n = 5$ –12 independent experiments; unpaired two-tailed t test. For *Sertm2* (C), *Mnx1* (D), and *Hoxc8* (E), the P values (Ctrl vs. KO) were <0.001 ($P = 1 \times 10^{-15}$), 0.94, and 0.62, respectively. (F) GDNF supplementation significantly increases *Etv4* transcript levels in Ctrl ESC-derived MNs but not *Sertm2* KO MNs. Data are shown as fold change (FC) relative to Ctrl [GDNF (–)] and represent mean \pm SD from $n = 13$ independent experiments; ordinary one-way ANOVA. $P < 0.001$ ($P = 1.57 \times 10^{-7}$) for GDNF (–) vs. (+) in Ctrl, $P = 0.11$ for GDNF (–) vs. (+) in KO, and $P < 0.001$ ($P = 3.57 \times 10^{-5}$) for GDNF (+) between Ctrl and KO. (G) E13.5 brachial spinal cord sections from Ctrl and KO mice were analyzed by in situ hybridization for *Sertm2*, combined with immunostaining for MN markers *Lhx3*, *Foxp1*, *Isl1*, and *Lhx1* to identify columnar MN subtypes. Circles demarcate LMC subtype (LMCl and LMCm), and dashed lines outline the spinal cord boundary. Scale bars: 50 μ m. (H) Immunostaining of the *Etv4*-expressing MN populations in E13.5 brachial spinal cord sections from Ctrl and KO mice. Brackets in the middle panel highlight co-expressing cells, while circles in the right panel indicate *Etv4*⁺ MN subtypes within LMC. Dashed lines outline the spinal cord boundary. Cutaneous maximus (CM), *Etv4*⁺*Isl1*⁺. Latissimus dorsi (LD), *Etv4*⁺*Isl1*⁺. Scale bar: 50 μ m. (I–L) Quantification of subsets of *Etv4*-expressing MNs in Ctrl and KO brachial spinal cords, as shown in (H). Data represent mean \pm SD from $n = 10$ independent biological samples, with three rostral-caudal sections per sample. Statistical analysis was performed using an unpaired two-tailed t test. For *Etv4*⁺ (I), *Foxp1*⁺ *Etv4*⁺ (J), *Etv4*⁺ *Isl1*⁺ (K), and *Etv4*⁺ *Isl1*[–] (L) MNs, the P values (Ctrl vs. KO) were 0.04, 0.01, 0.03, and 0.001, respectively.

major *Sertm2* transcript (*Sertm2*_UTR) and *Mnx1*⁺ cells remain stable despite the resulting frameshift in *Sertm2* (*Sertm2*_ORF) (Fig. 6B–D). Notably, whereas GDNF significantly induced *Etv4* expression in our control MNs, *Etv4* expression was markedly reduced in the FS-MNs (Fig. 6E), indicating that *Etv4* is primarily mediated through the *Sertm2* micropeptide.

To determine if *Sertm2* administration could rescue *Etv4* downregulation in the mouse *Sertm2* (full length 4.7 kb deletion) KO ESC-derived MNs, we utilized a lentivirus (LV) system to deliver either wild-type *Sertm2* (270 bp) or ATG-mutated *Sertm2* (as a control) into mouse *Sertm2* KO ESCs, which were then differentiated into MNs (Fig. 6F). Overexpression of *Sertm2* micropeptide in the mouse *Sertm2* KO cells was confirmed by western blot and qPCR, verifying both protein and RNA levels (Fig. 6G,H). We observed that ectopic expression of wild-type *Sertm2* protein, but not the mutant version, significantly rescued *Etv4* expression in the mouse KO cells (Fig. 6I), substantiating the evidence that *Sertm2* is a critical and functional micropeptide that modulates the GDNF-*Etv4* signaling pathway in MNs.

The function of human SERTM2 is conserved with that of murine *Sertm2*

Given that *Sertm2* is highly conserved among vertebrates (Fig. 2A), we sought to establish if its human ortholog, human *SERTM2* (a putative micropeptide derived from the lncRNA *LINC00890*), is conserved in terms of sequence, subcellular localization, and function. First, we assessed conservation of their exonic structures, sequences, and genomic positions (Guo et al, 2020; Ulitsky, 2016). According to GENCODE annotations, there are two *SERTM2* isoforms; the major isoform contains three exons, i.e., similar to mouse *Sertm2*, whereas the other isoform is shorter and only has two exons. Sequence analysis revealed that mouse *Sertm2* shares 91% similarity with the major human isoform (Fig. 7A). In addition, both genes have conserved upstream and downstream neighboring genes, namely *ALG13* and *DCX*, indicating that human *SERTM2* is conserved with murine *Sertm2* in terms of both sequence and genomic contexts (Fig. EV3C).

Next, we examined the expression pattern of human *SERTM2* during MN differentiation. To do so, we differentiated a human ESC line harboring the MN reporter (HuES3 MNX1::GFP) into

spinal MNs (Fig. 7B) (Di Giorgio et al, 2008), and then performed strand-specific RNA sequencing at three stages of differentiation, i.e., motor neuron progenitors (pMNs, Day 8), nascent postmitotic MNs (Day 16), and mature MNs with neurites (Day 31) (Figs. 7C and EV5B,C). Consistent with our findings in mouse MNs (Fig. 1B,C), we observed that human *SERTM2* was highly and specifically enriched in the postmitotic MNs. Notably, *GDNF* and its receptor *RET* were also strongly expressed in the mature MNs. These results were further validated by qPCR on MNs derived from another human induced pluripotent stem cell (iPSC) line harboring the MNX1-tdTomato (MNX1-tdT) reporter (Fig. 7D) (Garcia-Diaz et al, 2020).

Similar to mouse *Sertm2*, we found that human *SERTM2* predominantly localized in the cytoplasm of iPSC-derived MNs, using *GAPDH* and *U1* as controls for cytoplasmic and nuclear fractions, respectively (Fig. 7E). Moreover, to establish if the function of the GDNF-SERTM2-ETV4 axis is conserved in humans, we mutated the entire locus of *SERTM2* in the MNX1-tdT iPSC line (Figs. 7F and EV5D,E), and verified the absence of *SERTM2* expression from the resulting *SERTM2* mutant iPSC-MNs (KO) (Fig. 7G). Similarly, we also observed significant downregulation of *ETV4* expression, whereas columnar *FOXP1* expression was comparable to control (Fig. 7H,I). This result recapitulates the expression patterns we observed in our mouse *Sertm2* KO ESC-derived MNs and embryos (Fig. 4). Notably, we also observed a reduction in neurites, as revealed by the SMI-32 marker, in our *SERTM2* KO MNs (Fig. 7J–L). Together, these findings indicate that human *SERTM2* exerts a conserved role in *ETV4*⁺ MN subtype development, similar to *Sertm2* in mice.

Discussion

Recent research has unveiled that certain lncRNAs encode micropeptides, small proteins with crucial regulatory roles. These lncRNA-derived micropeptides are gaining recognition for their involvement in neural development, where they modulate key signaling pathways, influence neuronal differentiation, and contribute to axonal guidance and synaptic function (Duffy et al, 2022). These findings indicate that micropeptides may play previously unappreciated but essential roles in neural development and




Figure 5. Impact of impaired *Etv4*⁺ motor pools in *Sertm2* mutant mice.

(A, B) Neurite arborization in the latissimus dorsi (LD) muscle and cutaneous maximus (CM) muscle of E12.5 Ctrl; *Mnx1::GFP* and *Sertm2* KO; *Mnx1::GFP* (KO; *Mnx1::GFP*) mice, respectively. The magenta dashed squares in (A) indicate LD muscle regions, with axonal reconstructions displayed in (A'). Similarly, cyan brackets in (A) highlighted the CM muscle, with corresponding reconstruction in (A'). Scale bars: 100 μ m. (B) Presents the quantification of axonal branches in the LD muscle from (A', left), and innervation area of CM axons normalized to body length (right). Data represent mean \pm SD from $n = 3$ independent biological samples, with statistical analysis conducted using unpaired two-tailed *t* tests. $P = 0.03$ (LD) and $P = 0.02$ (CM) for Ctrl; *Mnx1::GFP* vs. KO; *Mnx1::GFP*. (C, D) A schematic of the balance beam test is shown in (C), featuring two beam diameters: 9 mm and 15 mm. (D) Presents the results for the 9-mm beam, comparing Ctrl and KO mice at P30 in terms of traversal time (left) and the number of foot slips (right). Data represent mean \pm SD from $n = 4$ –5 independent biological samples, with statistical analysis performed using an unpaired two-tailed *t* test. $P = 0.03$ (Latency to transverse) and $P = 0.02$ (Number of slips off) for Ctrl vs. KO. Results for the 15-mm beam are provided in Fig. EV4A. (E) Schematic representation of gait spatial characteristics in treadmill analysis. FR front right paw, FL front left paw, RR rear right paw, RL rear left paw. (F) Illustration of gait cycle paw contact area plots (red lines) along with gait parameters for each limb, including stride, stance, swing, break, and propulsion times, as assessed by treadmill analysis. (G) Treadmill walking parameters measured include (a) stride time, (b) stance time, (c) swing time, (d) brake time, and (e) propulsion time at three different walking speeds (10, 12.5, 15 cm/s) in P30 Ctrl and KO mice. Significant changes at a speed of 15 cm/s are highlighted in color in each panel. Data are presented as mean \pm SD from $n = 4$ –5 independent biological samples, with statistical analysis conducted using multiple unpaired *t* tests. All *P* values shown in the figures represent comparisons between Ctrl and KO. (H) Illustration of temporal interlimb coordination during walking, with phase intervals for pairs of limbs described below and examples highlighted in yellow. (I) Limb coordination (homolateral, homologous, and diagonal phase coupling) is represented as polar plots at different walking speeds. Phase values of 0 (or 1) correspond to perfect synchronization, while a phase value of 0.5 indicates strict alternation. The ideal phase values for each coordination type are highlighted in red and underlined. Statistical results for the speed of 15 cm/s are shown above each plot. Data are from $n = 4$ –5 independent biological samples at P30, analyzed using an unpaired two-tailed *t* test. $P = 0.30$ for homolateral, $P = 0.006$ for homologous, and $P = 0.54$ for diagonal comparisons between Ctrl and KO.

potentially in the progression of neurodegenerative diseases (Liaci et al, 2022; Salvatori et al, 2020). Notably, lncRNAs are highly enriched in the central nervous system (CNS), a pattern likely reflecting their critical functions in regulating gene expression, particularly during the complex processes of brain development and function (Srinivas et al, 2023). The tissue-specific and developmental stage-specific nature of lncRNA expression implies that they contribute to the fine-tuning of gene networks essential for neural development, synapse formation, and neural plasticity (Chen and Chen, 2020; Yen et al, 2018). This scenario raises a fascinating question, i.e., do CNS-enriched lncRNAs exert their functions primarily through their RNA molecules or do they act via encoded micropeptides? In this study, we have identified *Sertm2*, a lncRNA-derived micropeptide highly conserved across vertebrates, and rigorously demonstrated its functional role in neural development using genetic knockout and knock-in strategies. Furthermore, we employed micropeptide rescue experiments, widely regarded as the gold standard for validating the physiological functions of neuropeptides in vivo. Our findings establish a role for *Sertm2* in spinal MN differentiation and specification, providing compelling evidence for its significance in neural development.

Why do *Etv4*⁺ motor pools specifically require the function of the *Sertm2* micropeptide? In the spinal cord, MNs are organized along the rostrocaudal axis into distinct columnar types (Dasen et al, 2003). Within the limb LMCs, MNs are further grouped into more than sixty motor pools, each innervating a specific muscle. This organization is largely controlled by intrinsic mechanisms, particularly via a Hox-mediated clustering process, with most MN diversity being established early on, i.e., before MNs reach their final positions (Chen and Chen, 2019; Kania and Jessell, 2003; Sockanathan and Jessell, 1998). Interestingly, extrinsic signals from the periphery also play a critical role in motor pool identity. One such extrinsic factor is GDNF, initially known for its role in MN survival, but now recognized for its early presence in the developing forelimb plexus and later localization in the cutaneous maximus and latissimus dorsi muscles (Livet et al, 2002). In the absence of GDNF signaling, MNs that normally innervate these muscles are mispositioned within the spinal cord, and their axonal invasion of target muscles is significantly impaired. *Etv4*, a member of the ETS

family of transcription factors that is typically expressed by these MNs, fails to be induced in the absence of GDNF signaling, resulting in aberrant MN positioning and defective muscle innervation (Arber et al, 2000). Thus, GDNF acts as a peripheral signal to induce *Etv4* expression in specific MN pools, regulating both the positioning of MN cell bodies and their ability to innervate target muscles (Arber et al, 2000; Haase et al, 2002; Koo and Pfaff, 2002). Recent studies have indicated that *Hoxc8*, a key Hox protein expressed in the brachial spinal cord, regulates the expression of *Ret* and *Gfra* genes, which encode the receptor tyrosine kinases and GPI-anchored co-receptors, respectively, that mediate the effects of GDNF family ligands (Catela et al, 2016). *Hoxc8* confers sensitivity to peripheral GDNF signaling in a subset of MNs, enabling the induction of *Etv4* expression within specific motor pools (Catela et al, 2016). This mechanism ensures the precise fidelity of synaptic specificity within proprioceptive circuits (Shin et al, 2020). Given the role of GDNF in regulating *Etv4* expression and MN function, as a potential modulator of GDNF signaling, the *Sertm2* micropeptide may be essential for the proper differentiation and function of *Etv4*⁺ motor pools. In this study, we have identified *Sertm2* as a critical factor that modulates GDNF signaling to induce *Etv4* expression. *Sertm2* knockout results in significant impairment of the GDNF-induced *Etv4*⁺ motor pool, highlighting its essential role in this process. Moreover, we observed that the 3' UTR of *Sertm2* is enriched with ARE motifs, known to enable axonal trafficking (Loedige et al, 2023). This observation is supported by the enriched distribution of *Sertm2* mRNA in MN neurites, indicating a potential role for *Sertm2* in axonal transport. Notably, we observed that GDNF stimulation drastically increased *Sertm2* protein expression in both cell bodies and neurites, indicating that GDNF may promote *Sertm2* activity to autoregulate the GDNF-*Etv4* signaling axis. Further investigations, including deletion of the 5' and 3' UTRs of *Sertm2*, are warranted to identify the precise motifs responsible for induction of this micropeptide. Moreover, using *Sertm2*-Flag to pull down the mass spectrometry-determined *Sertm2* interactome in the spinal cord would enable the identification of possible candidates responsible for how *Sertm2* modulates the GDNF signaling pathway. Doing so would also clarify if *Sertm2* is locally induced at neuromuscular junctions or within MN cell




Figure 6. Sertm2 locus plays a role in regulating Etv4 expression via the micropeptide Sertm2.

(A) CRISPR/Cas9-induced frameshift mutation in the sORF of *Sertm2* in a mouse cell line carrying the *Mnx1::GFP* transgenic reporter, *Sertm2*^{Frameshift} (FS). The sgRNA targets the *Sertm2* sORF, resulting in a partial deletion. (B–D) qPCR analyses of the ORF and UTR regions of *Sertm2* (see Fig. 4A), and *Mnx1* in Ctrl and FS ESC-derived MNs. Data are presented as fold change (FC) relative to Ctrl and shown as mean \pm SD from $n = 3$ –4 independent experiments; unpaired two-tailed t test. P values for ORF, UTR, and *Mnx1* (Ctrl vs. FS) were 0.003, >0.99, and 0.43, respectively. (E) Consistent with mouse *Sertm2* KO MNs, *Etv4* RNA levels are reduced in FS ESC-derived MNs following the treatment shown in Fig. 4B. Data are presented as fold change (FC) relative to Ctrl [GDNF (–)] and shown as mean \pm SD from $n = 4$ –6 independent experiments; ordinary one-way ANOVA. $P < 0.001$ ($P = 2.22 \times 10^{-4}$) for GDNF (–) vs. (+) in Ctrl, $P = 0.54$ for GDNF (–) vs. (+) in FS, and $P = 0.004$ for GDNF (+) between Ctrl and FS. (F) Schematic illustration of lentivirus-mediated overexpression in *Sertm2* KO ESC-derived MNs. Plasmids containing either the wild-type (LV) or ATG-mutated sORF (LV- Δ ATG) of *Sertm2*, tagged with Flag, were packaged into lentiviruses and delivered into mouse *Sertm2* KO ESCs for subsequent MN differentiation. (G) Western blot analysis of lentivirus-mediated overexpression of Sertm2 protein following transfection. Flag indicates Sertm2 protein, and Gapdh serves as a loading control. (H, I) qPCR analyses of transduced MN culture reveal rescued expression of *Sertm2_ORF* (H) and *Etv4* RNA (I) in mouse *Sertm2* mutant ESC-MNs supplemented with GDNF. Data are shown as fold change (FC) relative to Ctrl, representing mean \pm SD from $n = 5$ –7 independent experiments; ordinary one-way ANOVA. $P < 0.001$ ($P = 4.58 \times 10^{-5}$ for Ctrl vs. KO; $P = 4.82 \times 10^{-5}$ for KO vs. LV; $P = 1.88 \times 10^{-5}$ for KO vs. LV- Δ ATG) in (H), while $P = 0.002$ for Ctrl vs. KO; $P = 0.014$ for KO vs. LV; $P = 0.998$ for KO vs. LV- Δ ATG in (I).

bodies, providing deeper insights into its regulatory role in GDNF-mediated MN function. While our study demonstrates that *Sertm2* plays a crucial role in the specification of *Etv4*⁺ MN pools, two intriguing questions remain. First, while our findings demonstrate the bona fide protein-coding potential of *Sertm2* as a conserved micropeptide, we cannot entirely rule out the possibility that *Sertm2* may also have additional regulatory functions within motor neurons. Interestingly, given that the host lncRNA, *A730046J19Rik*, is also significantly expressed in MN nuclei, it is plausible that

A730046J19Rik could possess both RNA- and protein-mediated functions (Mattick et al., 2023; Wright et al., 2022), which remain to be fully explored. Additionally, a previous study showed that the *Tug1* locus exerts three distinct regulatory functions: acting in *cis* to regulate neighboring genes; in *trans* to modulate distant gene expression; and as a peptide to influence mitochondrial membrane potential, all contributing to its essential role in male fertility (Lewandowski et al., 2020). It is tantalizing to probe the full spectrum of functions of the *A730046J19Rik* locus by deleting




Figure 7. Sequence and functional conservation of the human homolog SERTM2.

(A) Sequence comparison between human *SERTM2* and mouse *Sertm2* reveals that the homologous genes, located on the X chromosome, share 91% sequence similarity. (B) Timeline of differentiation of human ESCs or iPSCs into spinal MNs. Key markers for the indicated stages are shown in the figure. pMNs, motor neuron progenitors. (C) Heatmap showing the abundance of known transcription factors and genes of interest across the stages of differentiation of the human ESC line (HuES3 MNX1::GFP) into spinal MNs. The blue gradient represents the stage specificity score. The strand-specific RNA-seq data analyzed in this figure have been deposited in GEO under accession number GSE275447. (D) Expression profile of the *SERTM2* transcript in human iPSC (MNX1-tdT)-derived MNs. Data are presented as fold change (FC) relative to postmitotic MNs (Day 16), with mean \pm SD from $n = 3-4$ independent experiments; statistical analysis was performed using an unpaired two-tailed *t* test. $P = 0.083$ (postmitotic MNs vs pMNs) and $P = 0.368$ (postmitotic MNs vs mature MNs). (E) Subcellular fractionation of MNX1-tdT iPSC-derived MNs at Day 31 reveals significant *SERTM2* transcripts in the cytoplasm. *GAPDH* and *U1* serve as markers for the cytoplasmic and nuclear fractions, respectively. Data are presented as mean \pm SD from $n = 3-4$ independent experiments; multiple unpaired *t* tests. P values for *GAPDH*, *U1*, and *SERTM2* (Cytoplasm vs. Nuclear) were 0.002, <0.001 ($P = 1.37 \times 10^{-6}$), and <0.001 ($P = 3.24 \times 10^{-4}$), respectively. (F) Illustration of CRISPR/Cas9-mediated *SERTM2* deletion in the MNX1-tdT iPSC line referred to as KO. The paired sgRNAs targeted the entire *SERTM2* locus (dashed rectangle) on the X chromosome. Primers designed for genotyping and qPCR analyses are indicated in the figure. (G-I) qPCR analyses of Ctrl and KO iPSC-derived MNs at Day 31 reveal the downregulation of *SERTM2* and *ETV4* in the absence of *SERTM2*, whereas *FOXP1* expression remains unaffected. Data are presented as fold change (FC) relative to Ctrl, with mean \pm SD from $n = 3-5$ independent experiments; ordinary one-way ANOVA. Here, Ctrl refers to the MNX1-tdT iPSC line, whereas KO represents two CRISPR-mediated *SERTM2* mutant iPSCs (KO1 and KO2) used for qPCR analyses. P values for Ctrl vs. KO1 and Ctrl vs. KO2 in *SERTM2* (G) were $P < 0.001$ (8.52×10^{-9} and 7.49×10^{-9}); in *FOXP1* (H), they were $P = 0.953$ and 0.957 ; and in *ETV4* (I), they were $P < 0.001$ (9.88×10^{-4}) and 0.002 . (J) Brightfield microscopy-derived image of Ctrl and KO iPSC-derived MNs at Day 31. Scale bar, 200 μ m. (K, L) Validation of MN identity and morphology by immunostaining for ISL1 and SMI-32 at Day 31 of iPSC-MN differentiation (K). SMI-32 highlights neurite formation, while DAPI staining labels the nuclei. Scale bar, 50 μ m. Neurite complexity, quantified using ilastik, was normalized to the number of ISL1⁺ neurons and is shown in (L). Data are presented as mean \pm SD from $n = 4$ independent experiments; ordinary one-way ANOVA. P values for Ctrl vs. KO1 and Ctrl vs. KO2 were $P = 0.002$ and <0.001 ($P = 2.31 \times 10^{-4}$).

specific regions and examining the resulting physiological consequences will provide critical insights. Future studies employing more systematic approaches are necessary to investigate these potential multifaceted roles and further elucidate the broader regulatory functions of *Sertm2* and *A730046J19Rik* in MNs. Second, *Sertm2* is also expressed in MMC MNs, yet we did not observe a significant impact on MMC MN subtypes (i.e., *Nr2f2* and *Satb2*) in the spinal cords of *Sertm2* KO mice. Given that the protein size of *Sertm2* appears to vary in different cell contexts, it is likely that LMCs and MMCs might enforce distinct PTMs, thereby modifying *Sertm2* to have differential functions in MN subtypes, representing an uncharted domain for further research. Our findings highlight the conserved function of human *SERTM2* in iPSC-MNs, providing valuable insights into its evolutionary and functional conservation. However, the expression of the *SERTM2* micropeptide in specific human MN subtypes in vivo has yet to be confirmed. Recent advancements in spinal cord organoid technology (Gribaudo et al, 2024), which may better capture MN diversity in a human context, could help address this question and facilitate functional studies of *SERTM2* in human organoids.

The interplay between lncRNAs and their encoded peptides adds another layer of complexity to gene regulation in the CNS, indicating that a deeper investigation of micropeptides could yield insights into both development and disease. Our results open up new avenues for understanding the regulatory mechanisms at play during neural differentiation and raise intriguing possibilities for *Sertm2*'s involvement in neurodegenerative conditions. A recent study uncovered that the micropeptide SHMOOSE might be linked to Alzheimer's disease (Miller et al, 2023), but whether micropeptides exert functional roles during MN neurodegeneration remains largely unknown. Micropeptides are small and usually secreted, so deciphering their biological roles may reveal potential applications as disease biomarkers and pave the way for developing new drugs for neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). Given that GDNF is one of the critical targets for ongoing ALS clinical trials (Baloh et al, 2022), further study of the role of *Sertm2* in spinal MNs and if it may be exploited as a

biomarker and a new therapeutic target for ALS could prove illuminating. Overall, our study underscores the importance of considering both the RNA and peptide functions of lncRNAs in future research on neural development and neurodegeneration.

Methods

Reagents and tools table

Reagent/resource	Reference or source	Identifier or catalog number
Experimental models		
Mouse: Wild-Type C57BL/6 (B6) Mice	National Laboratory Animal Center	N/A
Mouse: <i>Sertm2</i> KO	This paper	N/A
Mouse: <i>Sertm2</i> -Flag (<i>Sertm2</i> KI)	This paper	N/A
Mouse: <i>Mnx1::GFP^{Tg/Tg}</i>	PMID:12176325	Dr. Hynek Wichterle (Columbia University)
Mouse: <i>Sertm2</i> KO; <i>Mnx1::GFP</i> (KO; <i>Mnx1::GFP</i>)	This paper	N/A
Mouse: <i>Sertm2</i> -Flag KI; <i>Mnx1::GFP</i> (KI; <i>Mnx1::GFP</i>)	This paper	N/A
Mouse: C57BL/6 (B6) ESC line	This paper	N/A
Mouse: <i>Sertm2</i> KO ESC line	This paper	N/A
Mouse: <i>Mnx1::GFP</i> ESC line	PMID:12176325	Dr. Hynek Wichterle (Columbia University)
Mouse: <i>Sertm2</i> -Flag; <i>Mnx1::GFP</i> ESC line (KI; <i>Mnx1::GFP</i>)	This paper	N/A
Human: MNX1-tdTomato iPSC line (MNX1-tdT)	PMID: 32615233	Dr. Hynek Wichterle (Columbia University)
Human: <i>SERTM2</i> KO; MNX1-tdTomato iPSC line (<i>SERTM2</i> KO; MNX1-tdT)	This paper	N/A

Reagent/resource	Reference or source	Identifier or catalog number
Human: HEK293T	Sigma-Aldrich	Cat# 12022001
Recombinant DNA		
pHRST-A730046J19Rik-ORF-Flag-IRES-eGFP	This paper	N/A
pHRST-mutATG-A730046J19Rik-ORF-Flag-IRES-eGFP	This paper	N/A
pENTR_D-TOPO	Invitrogen	K2400-20
pENTR/D-TOPO-Sertm2-Flag	This paper	N/A
pENTR/D-TOPO-mut-Sertm2-Flag	This paper	N/A
pLX301	Addgene	Plasmid #25895
pLX301-Sertm2-Flag	This paper	N/A
pLX301-mutATG-Sertm2-Flag	This paper	N/A
Antibodies		
Rabbit polyclonal anti-Lhx3 (1:1000)	Abcam	ab14555; RRID:AB_301332
Rabbit polyclonal anti-Foxp1 (1:20000)	Abcam	ab16645; RRID:AB_732428
Goat anti-Foxp1(1:100)	R&D systems	Cat# AF4534, RRID:AB_2107102
Goat polyclonal anti-Isl1 (1:1000)	Neuromics	GT15051; RRID:AB_2126323
Rabbit polyclonal anti-Etv4 (1:2000)	Thomas Jessell (Columbia University)	Cat# C115, RRID:AB_2631446
Rabbit anti-Lhx1 (1:20000)	Thomas Jessell (Columbia University)	Cat# CU453, RRID:AB_2827967
Goat polyclonal anti-ChAT (1:100)	Millipore	AB144P #NG1752017; RRID:AB_2079751
Mouse monoclonal anti-NeuN (1:500)	Millipore	Cat# MAB377, RRID:AB_2298772
Rabbit anti-Satb2 (1:1000)	Abcam	Cat# ab92446, RRID:AB_10563678
Rat anti-Bcl11b/Ctip2 (1:1000)	Abcam	Cat# ab18465, RRID:AB_2064130
Mouse anti-COUP-TF2/NR2F2 (1:200)	R&D systems	Cat# PP-H7147-00, RRID:AB_2155627
Mouse monoclonal anti-Neurofilament H, Nonphosphorylated (SMI-32) (1:1000)	BioLegend	801701 (clone SMI-32P); RRID:AB_2564642
Sheep anti-GFP (1:1000)	AbD Serotec/Bio-Rad	Cat# 4745-1051, RRID:AB_619712
Donkey anti-Sheep IgG (H + L) Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 488	Thermo Fisher Scientific	Cat # A-11015, RRID:AB_2534082
Donkey Anti-Goat IgG (H + L), Alexa Fluor™ 488	Thermo Fisher Scientific	Cat# A-11055, RRID:AB_2534102
488-AffiniPure Donkey Anti-Rat IgG (H + L)	Jackson ImmunoResearch Labs	Cat# 712-005-153, RRID:AB_2340631
Cy3-AffiniPure Donkey AntiGuinea Pig IgG (H + L)	Jackson ImmunoResearch Labs	Cat# 706-165-148, RRID:AB_2340460
Cy3-AffiniPure Donkey Anti-Mouse IgG (H + L)	Jackson ImmunoResearch Labs	Cat# 715-165-150, RRID:AB_2340813

Reagent/resource	Reference or source	Identifier or catalog number
Cy3-AffiniPure Donkey Anti-Rabbit IgG (H + L)	Jackson ImmunoResearch Labs	Cat# 711-165-152, RRID:AB_2307443
Cy5-AffiniPure Donkey AntiGuinea Pig IgG (H + L)	Jackson ImmunoResearch Labs	Cat# 706-175-148, RRID:AB_2340462
Cy5-AffiniPure Donkey Anti-Mouse IgG (H + L)	Jackson ImmunoResearch Labs	Cat# 715-175-150, RRID:AB_2340819
Cy5-AffiniPure Donkey Anti-Rabbit IgG (H + L)	Jackson ImmunoResearch Labs	Cat# 711-175-152, RRID:AB_2340607
Anti-Glyceraldehyde-3-Phosphate Dehydrogenase Antibody, clone 6C5 (GAPDH; 1:1000)	Millipore	Cat# MAB374, RRID:AB_2107445
DYKDDDDK Tag Monoclonal Antibody (FG4R) (Flag; 1:1000)	Thermo Fisher Scientific	Cat# MA1-91878, RRID:AB_1957945
DYKDDDDK tag Polyclonal antibody (Flag Rb; 1:2000)	ProteinTech	Cat# 20543-1-AP, RRID:AB_11232216
IRDye 800CW Goat anti-Rabbit IgG	LI-COR Biosciences	Cat# 926-32211, RRID:AB_621843
IRDye 680RD Goat anti-Mouse IgG	LI-COR Biosciences	Cat# 926-68070, RRID:AB_10956588
Oligonucleotides and other sequence-based reagents		
Primer for Genotyping		Table EV1
Primer for CRISPR-Cas9		Table EV1
Primer for construct		Table EV1
Primer for ISH probe		Table EV1
Primer for RT-qPCR		Table EV1
Chemicals, enzymes, and other reagents		
Retinoic acid (RA)	Sigma-Aldrich	Cat#R2625, CAS 302-79-4
Smoothened agonist (SAG)	Merck	Cat#566660, CAS 364590-63-6
Y-27632	Stemgent	Cat# 04-0012-10, CAS 129830-38-2
GSK-3 Inhibitor XVI (CHIR-99021)	Merck	Cat#361559, CAS 252917-06-9
SB431542	Merck	Cat#616461, CAS 301836-41-9
LDN 193189	Sigma-Aldrich	Cat#SML0559, CAS 1062368-24-4
γ-Secretase Inhibitor IX (DAPT)	Merck	Cat#565770, CAS 208255-80-5
Human BDNF	Peprotech	Cat#450-02
Rat GDNF	Peprotech	Cat#450-51
Human FGFb	Peprotech	Cat#100-18
L-Ascorbic acid	Sigma-Aldrich	Cat#A4544, CAS 50-81-7
Hexadimethrine bromide (polybrene)	Sigma-Aldrich	Cat#H9268, CAS 28728-55-4
PD98059	Merck	Cat#513000, CAS 167869-21-8
B27™ Supplement (50X), serum free	Gibco	Cat#17504044
N2 Supplement (100X)	Gibco	Cat#17502048

Reagent/resource	Reference or source	Identifier or catalog number
mPAGE™ 4-20% Bis-Tris Protein Gels	Millipore	Cat# MP42G10
Software		
Adobe Illustrator	Adobe	https://www.adobe.com
Adobe Photoshop	Adobe	https://www.adobe.com
GraphPad Prism version 10.0	GraphPad	https://www.graphpad.com
Zen Lite	Carl Zeiss	N/A
ImageJ	NIH	https://imagej.net/
R and RStudio	The R Foundation	N/A
University of California Santa Cruz (UCSC) genome browser	PMID: 36420891 (Nassar et al, 2023)	https://genome.ucsc.edu/
GWIPS-viz	PMID: 29927076 (Kiniry et al, 2018)	https://gwips.ucc.ie
PhyloCSF	PMID: 21685081 (Lin et al, 2011)	http://compbio.mit.edu/PhyloCSF
Phobius	PMID: 17483518 (Kall et al, 2007)	https://phobius.sbc.su.se
SignalP-6.0	PMID: 34980915 (Teufel et al, 2022)	https://services.healthtech.dtu.dk/service.php?SignalP-6.0
AlphaFold	Jumper et al, 2021; Varadi et al, 2024	https://alphafold.ebi.ac.uk/
smFISH and RNAScope		
Stellaris® FISH Probes	LGC Biosearch	
RNAScope® Multiplex Fluorescent Reagent Kit v2	ACD Bio	Cat. # 323100
RNAScope® Probe- Mm-A730046J19Rik-O1	ACD Bio	1136231-C1
RNAScope® Probe- Mm-Etv4-C2	ACD Bio	458121-C2
RNAScope® Probe- Mm-Nr2f2-C2	ACD Bio	480301-C2
RNAScope® Probe- Mm-Satb2-C3	ACD Bio	413261-C3
RNAScope® Probe- Mm-Isf1-C3	ACD Bio	451931-C3
Opal™ 520 Reagent Pack	ACD Bio	FP1487001KT
Opal™ 570 Reagent Pack	ACD Bio	FP1488001KT
Opal™ 690 Reagent Pack	ACD Bio	FP1497001KT

Mouse husbandry

All mice experimental procedures were approved and conducted according to the Institutional Animal Care and Use Committee (IACUC) guidelines at Academia Sinica (Protocol number 23-03-1991). *Sertm2* knockout and *Sertm2*-Flag KI mice were generated in-house. The strains of mice used in this study are summarized in the Reagents and Tools Table. All mice were maintained in conformity with specific pathogen-free (SPF) status. The animal housing environment was strictly controlled and monitored: 12-h light/dark cycle and 19–23 °C temperature with 40–60% humidity. We employed an equal number of male and female mice, matched for age and developmental stage as specified in the figure legends, and found no sex differences in this study.

Generation of CRISPR/Cas9-mediated *Sertm2* deletion and 3X-Flag epitope-tagged knock-in mice

Both *Sertm2* knockout, *Sertm2* frameshift, and *Sertm2*-Flag KI mice were generated in the C57BL/6 J background using the CRISPR/Cas9 system. A pair of single-guide RNA (sgRNA) was designed to target full-length *Sertm2* to induce *Sertm2* loss-of-function. To examine endogenous *Sertm2* micropeptide in the mouse model, a 3X-Flag tag was introduced at the C-terminus of *Sertm2* (corresponding to a conserved sORF within *A730046J19Rik*). The single-strand oligodeoxynucleotide (ssODN) was used for knock-in manipulation of the sORF within *Sertm2* via homology-directed repair (HDR) (Cong et al, 2013).

All designs of sgRNA sequences in this study were conducted using Breaking-Cas (<https://bioinfopg.cnbc.csic.es/tools/breakingcas/>). In addition, we assessed the off-target effects created by CRISPR/Cas9 via various computational tools to increase efficiency and mitigate the impact of unintended editing mutations. With the help of the Transgenic Core Facility (Institute of Molecular Biology, Academia Sinica), these CRISPR-modified mice were generated by delivery of Cas9 and the designed sgRNAs into the fertilized embryos of C57BL/6 mice. We then selected founder mice from the CRISPR/Cas9 strategy, and the manipulated region was verified using PCR and Sanger sequencing. A list of sgRNA targeting sequences, donor sequences, and genotyping primers is available in Table EV1.

Derivation and maintenance of mouse ESCs

To acquire the *Sertm2*^{KO} or *Sertm2*-Flag KI; Mnx1::GFP (KI; Mnx1::GFP) ESC lines, ESCs were directly derived from E3.5 blastocysts of designated mice. We adopted a mouse ESC derivation approach described previously (Tung et al, 2019). The derived blastocysts were cultured in KOSR ES (KES) medium: EmbryoMax DMEM (Millipore) containing Knockout-SR (Invitrogen), 1× EmbryoMax MEM Non-essential Amino Acids (Millipore), 1× Nucleosides (Millipore), 2 mM L-Glutamine (Invitrogen), 1% Penicillin/Streptomycin (Invitrogen), 0.00072% 2-mercaptoethanol (β-ME, Sigma), 0.02% leukemia inhibitory factor (LIF) (Millipore), 50 μM MEK1/MAPK inhibitors PD98059 (Merck), and 3 μM GSK-3β inhibitor CHIR-99021 (Merck). Maintenance of ESCs required co-culture with feeder cells in the ES medium [1× EmbryoMax DMEM (Millipore) supplemented with 15% Hyclone Fetal Bovine Serum (FBS) (GIBCO, 16000-044), 1× EmbryoMax MEM Non-essential Amino Acids, 1× Nucleosides, 2 mM L-Glutamine, 1% Penicillin/Streptomycin, 0.00072% β-ME, and LIF/ESGRO] and subculturing using 0.05% Trypsin-EDTA (Gibco) every three days. All cell lines were maintained at 37 °C in a 5% CO₂ cell culture incubator and routinely tested for mycoplasma contamination by genotyping with the respective primers listed in Table EV1.

Mouse motor neuron differentiation

Stable mouse ESCs were cultured and differentiated into spinal MNs as described previously (Wichterle et al, 2002; Wichterle et al, 2009; Yen et al, 2018). At Day 2 of differentiation, cells were cultured in ADFNK medium supplemented with 1 μM of retinoic acid (RA, Sigma-Aldrich) and 500 nM of smoothened agonist (SAG, Merck) until Day 5 when cells reached the postmitotic state. Afterward, embryoid bodies (EBs) were dissociated by Accutase

(Gibco) and plated onto poly-L-orithine/laminin-coated four-well plates with coverslips. From Day 5 onward, the cells were either left untreated or induced with recombinant GDNF (10–30 ng/mL, Peprotech) in MN culture medium [ADFNK medium containing N2 (Life Technologies) and B27 (Life Technologies)] (Peljto et al, 2010).

Culture and differentiation of human ESC or iPSC-derived MNs

The human iPSC line MNX1-tdTomato (iPSC MNX1-tdT, SalvaRED) was acquired from Dr. Hynek Wichterle (Garcia-Diaz et al, 2020). The *SERTM2* knockout cell line (*SERTM2*^{KO}) was generated in-house by the CRISPR/Cas9 gene editing system (Ran et al, 2013) in the MNX1-tdT background. In brief, MNX1-tdT cells were nucleofected using a 4D-Nucleofector (Lonza) with targeting sgRNAs (Table EV1). After 24 h of nucleofection, drug selection was performed with puromycin (0.3 µg/mL) for three days. The selected cells were isolated and then subjected to PCR-based genotyping, with primer sequences provided in Table EV1.

Human ESCs (HuES3 MNX1::GFP) (Di Giorgio et al, 2008) or iPSCs (MNX1-tdT [Ctrl] and *SERTM2*^{KO}; MNX1-tdT [KO]) were maintained on vitronectin (Gibco) at 37 °C and 5% CO₂ in Essential 8 medium (Life Science) and subcultured using 0.5 mM EDTA (Invitrogen) every 3 days. All cell lines used in this study are shown in the Reagents and Tools Table.

All human cell lines were dissociated with Accutase and differentiated towards MNs according to a method described previously (Maury et al, 2015; Tung et al, 2019). In brief, cells were cultured in N2/B27 medium consisting of a 1:1 mixture of DMEM-F12 and Neurobasal medium containing N2, B27, 1% Penicillin/Streptomycin, 2 mM Glutamax, 0.2 mM β-ME, 0.5 µM ascorbic acid (Sigma-Aldrich), 10 µM Y-27632 (STemGent), 20 µM SB431542 (Merck), 0.1 µM LDN 193189 (Sigma-Aldrich), 3 µM CHIR-99021 (Merck), and 10 ng/mL bFGF (Peprotech). The formation of EBs occurred after 2 days of differentiation. SB431542 and LDN 193189 were supplemented for 4 days, and 100 nM RA and 0.5 µM SAG were added from Day 2 to 16. BDNF (10 ng/mL, Peprotech) was added from Day 7, and 10 µM of DAPT (Calbiochem) was included from Day 9 to Day 16. At Day 11 of differentiation, EBs were dissociated by Accutase and then plated on poly-L-ornithine/laminin-coated four-well plates at a density of 5 × 10⁴ cells per well. Dissociated MNs were cultured in MN culture medium [CultureOne Supplement medium (Gibco) containing 10 µM Y-27632, 10 ng/mL BDNF, 10 ng/mL GDNF, and 10 µM 5-fluoro-2'-deoxyuridine (FdU)/Uridine (to inhibit proliferating cells, Merck)] from Day 16 until Day 31 when the cultures were analyzed. The medium was replenished every 3–5 days.

Dissociated MNs (human iPSC-derived MNs) were fixed in 4% paraformaldehyde (PFA) for 30 min at 4 °C and rinsed with PBS. Characterization of iPSC-derived MNs was performed using immunostaining, with images acquired using an ImageXpress® Micro XLS High-Content Imaging System (Molecular Devices) or LSM 780 upright confocal microscope (ZEISS) (Chen et al, 2023; Tung et al, 2019). The neurite complexity was assessed using automated image analysis with ilastik (Berg et al, 2019) and ImageJ/Fiji plugins.

cDNA library construction and sequencing

For low-input stranded RNA-seq, 100 ng of total RNA was harvested from human ESC-derived MNs (HuES3 MNX1::GFP) at the indicated time points (Day 8, Day 16, and Day 31) during MN differentiation, using two, three, and two biological replicates, respectively, for cDNA library construction. cDNA libraries were prepared with a TruSeq Stranded Total RNA Ribo-zero Plus kit and a TruSeq mRNA Stranded Library Prep kit. The seven libraries were sequenced on a Next-seq 500 system (Illumina) using a 75 pair-ended approach. Approximately, 80–100 million reads were generated from each library. The raw sequence reads in FASTQ format were generated for further analysis.

Stranded RNA-seq analysis

Adapter contamination in the paired-end reads was removed using PEAT (Li et al, 2015), and the trimmed reads were aligned to GRCh38 using STAR aligner (Dobin et al, 2013). Standard GTF-formatted transcript annotation was defined according to GRCh38 (Harrow et al, 2012), which includes many evidence-based lncRNAs. We used this annotation to aid in junction read alignment in STAR, the output of which was submitted to Cufflinks (Trapnell et al, 2010) for de novo transcript assembly with the option 'library type; first-strand' to allow strand-specific alignments. We calculated the specificity score of each transcript among the samples at different stages using the Jensen–Shannon definition for tissue specificity scores (Cabili et al, 2011; Trapnell et al, 2010; Yen et al, 2018), for which specificity score distributions were plotted and compared.

Mouse tissue collection

For spinal cord collection from mouse embryos, mice were crossed at the age of 8 ~ 12 weeks to obtain embryos of desired genotypes. When a vaginal plug was observed, the embryos were considered as embryonic day (E) E0.5. At E9.5–E13.5, pregnant mice were euthanized by cervical dislocation, and then embryos were isolated for further study. After removing the head and internal organs, the embryos were immersed in 4% PFA for ~1–2 h (for immunostaining), 4 h (for in situ hybridization), or overnight (for RNAscope) at 4 °C, followed by a PBS wash. Spinal cords were cryoprotected in 30% sucrose and embedded in FSC 22 frozen section media (Leica) before sectioning. Cryostat slices of 20 µm (for immunostaining and in situ hybridization) or 12 µm (for RNAscope) were prepared using a CM3050S Cryosectioning System (Leica). Samples were stored at –80 °C prior to downstream processing.

Neonatal mice (less than postnatal day (P) 10 in age) were anesthetized using hypothermia and then transcidentally perfused with cold PBS, followed by 4% PFA post-fixation overnight. The same procedures described above for cryosectioning were used for neonatal samples.

Immunohistochemistry

Immunohistochemistry of mouse embryos was performed on 20-µm cryostat sections as described previously (Li et al, 2017; Liau et al, 2023). During experimental procedures, sections were

permeabilized and blocked with 10% FBS plus 0.5% Triton X-100 for 1 h at room temperature. Primary antibodies were applied and incubated at 4 °C overnight. Subsequently, sections were washed frequently with 0.01% Triton X-100/PBS. Species-specific Alexa Fluor secondary antibodies (Jackson ImmunoResearch) were applied at room temperature for 2 h of incubation. Finally, samples were washed with PBS and mounted with Aqua-Poly/Mount (Polysciences Inc.).

Spinal cord sections from neonatal mice were permeabilized in 0.3% Triton X-100/PBS for 1 h and blocked in 3% bovine serum albumin (BSA) in 0.3% Triton X-100/PBS for 30 min at room temperature. The sections were then incubated with indicated primary antibodies in the blocking solution at 4 °C over two nights. After PBS washes, the sections were immersed with secondary antibodies and DAPI in the permeabilized buffer for 1 h at room temperature. After further PBS washes, the sections were mounted.

Commercially available primary antibodies and antibodies gifted by H. Wichterle and TM Jessell used at respective titers are described in the Reagents and Tools Table. All immunostaining samples were subsequently imaged with a ZEISS LSM 780 upright confocal microscope.

In situ hybridization (ISH)

Samples were prepared for in situ hybridization as described previously (Hsu et al, 2024). In brief, samples were post-fixed with 4% PFA for 15 min and rinsed with 1× PBS at room temperature. Proteinase K (2 µg/mL, Roche) treatment was applied for 10 min, followed by acetylation in acetic anhydride/triethanolamine (Sigma-Aldrich) for 10 min. After pre-hybridization in hybridization solution [50% formamide, 5× saline-sodium citrate (SSC), 5× Denhardt's solution (Fisher), 250 µg/mL yeast tRNA (Ambion), 0.5 mg/mL salmon sperm DNA (Thermo Fisher Scientific), 2% Roche blocking reagent] for at least 3 h, a digoxigenin (DIG)-labeled RNA probe (100–150 ng) was hybridized into sections overnight at 58 °C. Next, the slides were frequently washed in 2× SSC and then in 0.2× SSC at 55 °C. After blocking with blocking solution [1% BMB (1,4-bismaleimidobutane) and 10% fetal bovine serum in maleic acid buffer (MAB; 100 mM maleic acid, 150 mM sodium chloride)], the sections were incubated with anti-digoxigenin-AP, Fab fragments overnight at 4 °C. Finally, the slides were processed with NBT/BCIP solution (Roche), allowing a color reaction. The sequence for ISH riboprobe generation is provided in Table EV1 and the template DNA was amplified by PCR. Images were captured from projections of a Zeiss AxioImager Z1 upright microscope.

Single-molecule RNA fluorescence in situ hybridization (smFISH)

Mouse ESC-derived MNs were cultured on poly-L-ornithine/laminin-coated coverslips in MN culture medium. Cells were harvested on the designated day and fixed in 3.7% formaldehyde in DEPC-treated PBS for 10 min at room temperature, permeabilized for 5 min on ice in PBS with 0.5% Triton X-100, followed by immersing in 70% EtOH for subsequent RNA FISH (Yen et al, 2018). Samples were washed in wash buffer [10% deionized formamide in 2× SSC] for 5 min and then incubated with a 1:100 mouse *A730046J19Rik* smFISH probe (Stellaris®, see Reagents and

Tools Table) in hybridization buffer [10% deionized formamide, 0.1 g/mL dextran sulfate (Millipore) in 2X SSC] in the dark within a humidity chamber at 37 °C for 4–16 h. The sections were mounted with VECTASHIELD Antifade Mounting Medium (VECTOR) before undergoing imaging with a Delta Vision microscopy system.

For RNA quantification, we extracted reliable information from the images by generating maximum intensity projections of the z-stacks using ImageJ. Following the guidelines outlined in a previous study (Patel et al, 2021), we quantified the number of spots in different cellular regions and calculated their enrichment across various fractions.

RNAscope

RNAscope was performed on 12-µm spinal cord sections or mouse ESC-derived MNs using a RNAscope Multiplex Fluorescent Reagent Kit v2 (Advanced Cell Diagnostics, Cat. No. 323100), and probes were detected with Akoya Biosciences Opal 520 (Cat. No. FP1487001KT), 570 (FP1488001KT), and 690 (FP1497001KT). Sample preparation and staining procedures were performed according to the manufacturer's guidelines. In brief, RNAscope probes were hybridized for 2 h at 40 °C. Next, signal amplification and channel development were conducted sequentially, before counterstaining with DAPI and mounting with VECTASHIELD Antifade Mounting Medium (VECTOR). Further details of the probes are presented in the Reagents and Tools Table. Samples were examined using a ZEISS LSM 780 upright confocal microscope.

Innervation analysis

Experimental procedures to visualize axon arborization patterns in mouse embryos were performed as described previously (Liau et al, 2018; Yen et al, 2018). The *Sertm2* mutant mice were outcrossed with transgenic *Mnx1::GFP* mice to investigate the possible defects in motor axon arborization. The embryos (E12.5) were fixed in 4% PFA for 1 h at 4 °C, permeabilized in 0.5% PBS-Triton X-100 (PBST), blocked with 10% FBS, and then processed for whole-mount GFP staining at 4 °C with constant shaking. After several washes, embryos were cut in half along the spinal cord. Finally, the preparations were incubated in RapiClear® (RI = 1.49; SUNJIN LAB) to render the embryo transparent for imaging. Maximum intensity projections of z-stack images were collected on Zeiss LSM980 with Airyscan confocal microscopes. Motor innervation patterns of the cutaneous maximus (CM) and latissimus dorsi (LD) muscles of each genotype were processed and quantified using Imaris Microscopy Image Analysis Software (Oxford).

RNA isolation and quantitative real-time PCR (qPCR)

Trizol (Thermo Fisher Scientific) was used to harvest total RNA from samples. We extracted RNA by conventional chloroform phase separation, followed by isopropanol precipitation. The resulting white pellet was washed in a cold 70% ethanol solution, air-dried, and resuspended in DEPC-treated double distilled water.

Total RNA (0.5–1.0 µg) from each sample was reverse-transcribed into cDNA using Superscript III (Invitrogen). The product of the reverse transcription reaction was applied to subsequent qPCR reactions, which were conducted in technical

replicates and underwent a melt curve analysis on a LightCycler480 Real-Time PCR instrument (Roche) using SYBR Green PCR mix (TOOLS, FPT-BB05) for each gene of interest. The geometric mean of the reference gene (*Gapdh* and *GAPDH* for mouse and human, respectively) Ct values were determined and expression levels of the genes of interest were normalized using the $2^{-\Delta\Delta CT}$ formula. Primers for quantitative PCR analysis are listed in Table EV1.

Subcellular RNA fractionation

Isolation of subcellular fractions was performed as described previously (Gagnon et al, 2014; Yen et al, 2018). In brief, EBs at desired time points were collected and subcellular components were separated. The pellets of dissociated EBs were resuspended in 200 μ l hypotonic lysis buffer [10 mM Tris (pH 7.5), 10 mM NaCl, 3 mM MgCl₂, 0.3% NP-40, 10% glycerol], incubated on ice for 10 min, and spun at 1000 \times g for 5 min. The supernatant was collected as the cytoplasmic fraction, and the remaining pellets were further processed to extract the nuclear/chromatin fraction. Modified Wuariin-Schibler (200 μ l, MWS) buffer supplemented with RNase-OUT and DTT were added to pellets, before incubating on ice for 10 min. After centrifuging, the supernatant and pellet were saved as the nuclear and chromatin fractions, respectively. Trizol (Thermo Fisher Scientific) was then used to extract RNA, which was subjected to reverse transcription with hexamer primers. Finally, to assess the qualities of the different subcellular fractions, we determined expression levels by qPCR of *U1* (*RNU1*, a snRNA in the nucleus) and *GAPDH* as markers of the nucleus and cytoplasm, respectively. The relevant primers are listed in Table EV1.

Western blotting

Cell and tissue lysates were prepared by lysing samples in RIPA lysis buffer [0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 5 mM EDTA, 150 mM NaCl, 50 mM Tris-HCl pH 8.0] with freshly added protease inhibitor cocktail (Roche) and phenylmethylsulfonyl fluoride (PMSF). After incubating on ice for 15 min, the lysates were clarified by centrifugation at 12,000 \times g for 15 min at 4 °C. Protein concentration was determined using a BCA Protein Assay kit (Thermo Fisher).

Proteins were loaded onto mPAGE™ Bis-Tris Precast SDS-PAGE Gels (Merck) and run in 1 \times MES SDS running buffer [Tris-Base, MES, SDS, EDTA] at 180 V for ~30 min, followed by 1 h at 100 V in transfer buffer [25 mM Tris-Base, 25 mM Bicine, 10% Methanol]. Next, we subjected the membranes to blocking with 5% silk milk for 1 h at room temperature, before incubating them with primary antibodies at 4 °C overnight. Appropriate IRDye® secondary antibodies (LiCOR) corresponding to the species of the primary antibody were then applied. Membranes were imaged using an Amersham Biosciences Typhoon biomolecular laser scanner (GE Healthcare). The antibodies used in this study are described in the Reagents and Tools Table.

HEK293T cell culture and transfection

Human embryonic kidney (HEK293T) cells were grown in DMEM (Gibco) supplemented with 2 mM L-Glutamine (Invitrogen), 1% Penicillin/Streptomycin (Invitrogen), and 10% FBS (Gibco) in a 5% CO₂ and 37 °C incubator.

HEK293T cells were plated at a density of 0.5–1 \times 10⁵ per well on a four-well plate (with or without coverslips), cultured for the indicated times, and co-transfected with different combinations of plasmids using the commercially available transfection reagent Lipofectamine™ LTX (Invitrogen). Experimental procedures were conducted according to the manufacturer's recommendations. The use of pEGFP-C1 expressing green fluorescent protein (GFP) allowed us to determine transfection success. Cells were harvested 24–48 h after transfection and either lysed in RIPA lysis buffer or fixed with 4% PFA for further experimentation. Plasmids used in this study are detailed in the Reagents and Tools Table.

Lentivirus preparation and transduction of mESCs-derived MNs

Sertm2 (corresponding to a conserved sORF within *A730046J19Rik*) and the ATG mutant of Sertm2 (Δ ATG) were subcloned into pENTR/D-TOPO entry vector. Gateway cloning technology was applied to exchange the target sequence into the Gateway-compatible pLX301 lentiviral plasmid (a gift from David Root; Addgene plasmid # 25895). *Sertm2* KO ESCs were transduced in the presence of 8 μ g/mL polybrene. Transduced cells were subsequently subjected to antibiotic selection with puromycin to generate stable cell lines carrying Sertm2 or mutated Sertm2. LV-Sertm2 (LV) and LV-mutATG-Sertm2 (LV- Δ ATG) were packaged by the National RNAi Core Facility (Academia Sinica, Taiwan).

Mouse motor assessment

Animals were assessed for baseline weight and subjected to behavioral tests at different ages. To minimize the impact of the confounding variable of animal handling, mice were transferred to and habituated in the test room before experiments. Littermate controls or age-matched wild-type (C57BL/6) mice served as a reasonable control for experimental comparisons. Treadmill and beam walking tests were conducted on P30 mice, whereas grip strength and rotarod tests were performed on P90 and P120 mice. At least three measurements were taken from each mouse to get an average result for statistical analysis. All behavioral assays were conducted by experimenters who were blinded to the mouse genotypes.

Rotarod test

Motor coordination and performance were measured using a Rota-Rod (47650 Rota-Rod, Ugo Basile). All mice were subjected to a training course with a constant speed of 4 rpm before the assay. A steadily accelerating rotation speed, from 4 to 40 rpm over 300 s, was applied to measure the latency for mice to fall off the apparatus. The time to fall off or grasp the rod without running was considered the falling latency.

Grip strength

The Grip Strength Test (Bio-GS3, BIOSEB) determined the gripping strength of the forelimbs of mice. While placed on the grid, mice were pulled back by the tail, keeping the torso horizontal and allowing only the forepaws to attach to the test grid. The maximal grip strength of the mouse was displayed on the screen of

the Bio-GS3 apparatus. This procedure was repeated for at least three consecutive trials, and results were recorded for further analysis. To mitigate concerns that differential body weight could account for any differences, grip strength values were normalized against mouse body weight.

Beam walking assay

The beam walking test was conducted using a narrow wooden beam 60 cm long and positioned 40 cm above a bench. Prior to testing, mice were trained to transverse a 15-mm beam 3–5 times. Subsequently, mice were subjected to two trials (15 mm and 9 mm rectangular beams) with a cut-off period of 3–5 min per trial and an intertrial interval of 20–30 min. Each trial was video-recorded from a lateral view to capture performance. Manual analysis included measuring and analyzing the number of segments crossed, beam crossing latencies, and slippage events.

Treadmill locomotion analysis

A TreadScan apparatus (CleverSys, Reston, VA) was used to analyze gait. Mice were placed on a stationary treadmill for acclimation and trained at a speed of 8 cm/s for 5 min before testing. Three test speeds were analyzed (10, 12.5, and 15 cm/s) for each trial, which were recorded at 79 frames/s for 10 s using the TreadScan software. For data analyses, successful trials in which a mouse could maintain the treadmill speed with continuous locomotion for each of the 10-s recordings were selected and further analyzed using TreadScan software. The gait parameters for each limb—including stride, stance, swing, break, and propulsion time—were automatically and unbiasedly calculated, and average values were used for statistical analysis.

The parameters for limb coordination (phase coupling) were also calculated using TreadScan software, and the average values for homologous, homolateral, and diagonal coupling for each hindlimb from all trials were statistically analyzed. The phase coupling parameter is graphically displayed as a circular plot with phase values of 0 or 1 corresponding to perfect synchronization, whereas a phase value of 0.5 represents strict alternation. The mean phase value is indicated by the direction of the vector, and vector length represents the concentration of phase values around the mean (Chang et al, 2021; Crone et al, 2009). Data visualization was performed in R.

Statistical analysis and graphical representations

GraphPad Prism 10.0 (GraphPad Software) was used to perform all statistical analyses, i.e., *t* test or one-way ANOVA, as indicated in the figure legends. Quantitative data are presented as mean \pm SD (standard deviation) of three or more independent biological replicates. The respective *P* values from statistical analyses are shown in the figures.

Graphics

BioRender (<https://www.biorender.com>) was used to create the schematics shown in Figs. 1A, 5C,E,H, and 6F, and the synopsis for this study.

Data availability

The datasets and computer code produced in this study are available in the following databases: RNA-seq data: Gene Expression Omnibus [GSE275447](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275447). The public datasets utilized in this study are listed as follows: RNA-seq data: Gene Expression Omnibus [GSE114285](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114285) (Yen et al, 2018). Single-cell RNA-sequencing data: Gene Expression Omnibus [GSE183759](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE183759) (Liau et al, 2023).

The source data of this paper are collected in the following database record: [biostudies:S-SCDT-10_1038-S44319-025-00400-0](https://www.ncbi.nlm.nih.gov/biostudies/record/S-SCDT-10_1038-S44319-025-00400-0).

Expanded view data, supplementary information, appendices are available for this paper at <https://doi.org/10.1038/s44319-025-00400-0>.

Peer review information

A peer review file is available at <https://doi.org/10.1038/s44319-025-00400-0>

References

- Anderson DM, Anderson KM, Chang CL, Makarewich CA, Nelson BR, McAnally JR, Kasaragod P, Shelton JM, Liou J, Bassel-Duby R et al (2015) A micropeptide encoded by a putative long noncoding RNA regulates muscle performance. *Cell* 160:595–606
- Arber S, Ladle DR, Lin JH, Frank E, Jessell TM (2000) ETS gene *Er81* controls the formation of functional connections between group Ia sensory afferents and motor neurons. *Cell* 101:485–498
- Baloh RH, Johnson JP, Avalos P, Allred P, Svendsen S, Gowing G, Roxas K, Wu A, Donahue B, Osborne S et al (2022) Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1/2a trial. *Nat Med* 28:1813–1822
- Berg S, Kutra D, Kroeger T, Straehle CN, Kausler BX, Haubold C, Schiegg M, Ales J, Beier T, Rudy M et al (2019) *ilastik*: interactive machine learning for (bio) image analysis. *Nat Methods* 16:1226–1232
- Biscarini S, Caputo D, Peruzzi G, Lu L, Colantoni A, Santini T, Shneider NA, Caffarelli E, Laneve P, Bozzoni I (2018) Characterization of the lncRNA transcriptome in mESC-derived motor neurons: Implications for FUS-ALS. *Stem Cell Res* 27:172–179
- Briggs JA, Wolvetang EJ, Mattick JS, Rinn JL, Barry G (2015) Mechanisms of long non-coding RNAs in mammalian nervous system development, plasticity, disease, and evolution. *Neuron* 88:861–877
- Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, Rinn JL (2011) Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. *Genes Dev* 25:1915–1927
- Catela C, Shin MM, Lee DH, Liu JP, Dasen JS (2016) Hox proteins coordinate motor neuron differentiation and connectivity programs through *Ret/Gfralpha* genes. *Cell Rep* 14:1901–1915
- Chang SH, Su YC, Chang M, Chen JA (2021) MicroRNAs mediate precise control of spinal interneuron populations to exert delicate sensory-to-motor outputs. *eLife* 10:e63768
- Chen KW, Chen JA (2020) Functional roles of long non-coding RNAs in motor neuron development and disease. *J Biomed Sci* 27:38
- Chen TH, Chang SH, Wu YF, Yen YP, Hsu FY, Chen YC, Ming Y, Hsu HC, Su YC, Wong ST et al (2023) *MiR34* contributes to spinal muscular atrophy and AAV9-mediated delivery of *MiR34a* ameliorates the motor deficits in SMA mice. *Mol Ther Nucleic Acids* 32:144–160

- Chen TH, Chen JA (2019) Multifaceted roles of microRNAs: from motor neuron generation in embryos to degeneration in spinal muscular atrophy. *eLife* 8:e50848
- Choi W, Wu H, Yserentant K, Huang B, Cheng Y (2023) Efficient tagging of endogenous proteins in human cell lines for structural studies by single-particle cryo-EM. *Proc Natl Acad Sci USA* 120:e2302471120
- Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA et al (2013) Multiplex genome engineering using CRISPR/Cas systems. *Science* 339:819–823
- Crone SA, Zhong G, Harris-Warrick R, Sharma K (2009) In mice lacking V2a interneurons, gait depends on speed of locomotion. *J Neurosci* 29:7098–7109
- Dasen JS, De Camilli A, Wang B, Tucker PW, Jessell TM (2008) Hox repertoires for motor neuron diversity and connectivity gated by a single accessory factor, FoxP1. *Cell* 134:304–316
- Dasen JS, Jessell TM (2009) Hox networks and the origins of motor neuron diversity. *Curr Top Dev Biol* 88:169–200
- Dasen JS, Liu JP, Jessell TM (2003) Motor neuron columnar fate imposed by sequential phases of Hox-c activity. *Nature* 425:926–933
- Dasen JS, Tice BC, Brenner-Morton S, Jessell TM (2005) A Hox regulatory network establishes motor neuron pool identity and target-muscle connectivity. *Cell* 123:477–491
- Di Giorgio FP, Boulting GL, Bobrowicz S, Eggan KC (2008) Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. *Cell Stem Cell* 3:637–648
- Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR (2013) STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29:15–21
- Duffy EE, Finander B, Choi G, Carter AC, Pritisanac I, Alam A, Luria V, Karger A, Phu W, Sherman MA et al (2022) Developmental dynamics of RNA translation in the human brain. *Nat Neurosci* 25:1353–1365
- Ferrando RE, Newton K, Chu F, Webster JD, French DM (2015) Immunohistochemical detection of FLAG-tagged endogenous proteins in knock-in mice. *J Histochem Cytochem* 63:244–255
- Gagnon KT, Li L, Janowski BA, Corey DR (2014) Analysis of nuclear RNA interference in human cells by subcellular fractionation and Argonaute loading. *Nat Protoc* 9:2045–2060
- Galindo MI, Pueyo JI, Fouix S, Bishop SA, Couso JP (2007) Peptides encoded by short ORFs control development and define a new eukaryotic gene family. *PLoS Biol* 5:e106
- Garcia-Diaz A, Efe G, Kabra K, Patel A, Lowry ER, Shneider NA, Corneo B, Wichterle H (2020) Standardized reporter systems for purification and imaging of human pluripotent stem cell-derived motor neurons and other cholinergic cells. *Neuroscience* 450:48–56
- Gribaudo S, Robert R, van Sambeek B, Mirdass C, Lyubimova A, Bouhali K, Ferent J, Morin X, van Oudenaarden A, Nedelec S (2024) Self-organizing models of human trunk organogenesis recapitulate spinal cord and spine co-morphogenesis. *Nat Biotechnol* 42:1243–1253
- Guo CJ, Ma XK, Xing YH, Zheng CC, Xu YF, Shan L, Zhang J, Wang S, Wang Y, Carmichael GG et al (2020) Distinct processing of lncRNAs contributes to non-conserved functions in stem cells. *Cell* 181:621–636.e622
- Haase G, Dessaud E, Garcés A, de Bovis B, Birling M, Filippi P, Schmalbruch H, Arber S, deLapeyriere O (2002) GDNF acts through PEA3 to regulate cell body positioning and muscle innervation of specific motor neuron pools. *Neuron* 35:893–905
- Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, Aken BL, Barrell D, Zadissa A, Searle S et al (2012) GENCODE: the reference human genome annotation for The ENCODE Project. *Genome Res* 22:1760–1774
- Hassel KR, Brito-Estrada O, Makarewich CA (2023) Microproteins: overlooked regulators of physiology and disease. *iScience* 26:106781
- Helmbacher F, Dessaud E, Arber S, deLapeyriere O, Henderson CE, Klein R, Maina F (2003) Met signaling is required for recruitment of motor neurons to PEA3-positive motor pools. *Neuron* 39:767–777
- Hong D, Jeong S (2023) 3'UTR diversity: expanding repertoire of RNA alterations in human mRNAs. *Mol Cells* 46:48–56
- Hsu HC, Hsu SP, Hsu FY, Chang M, Chen JA (2024) LncRNA Litchi is a regulator for harmonizing maturity and resilient functionality in spinal motor neurons. *iScience* 27:109207
- Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Zidek A, Potapenko A et al (2021) Highly accurate protein structure prediction with AlphaFold. *Nature* 596:583–589
- Kall L, Krogh A, Sonnhammer EL (2007) Advantages of combined transmembrane topology and signal peptide prediction—the Phobius web server. *Nucleic Acids Res* 35:W429–432
- Kania A, Jessell TM (2003) Topographic motor projections in the limb imposed by LIM homeodomain protein regulation of ephrin-A:EphA interactions. *Neuron* 38:581–596
- Kiniry SJ, Michel AM, Baranov PV (2018) The GWIPS-viz Browser. *Curr Protoc Bioinformatics* 62:e50
- Koo SJ, Pfaff SL (2002) Fine-tuning motor neuron properties: signaling from the periphery. *Neuron* 35:823–826
- Ladle DR, Frank E (2002) The role of the ETS gene PEA3 in the development of motor and sensory neurons. *Physiol Behav* 77:571–576
- Lewandowski JP, Dumbovic G, Watson AR, Hwang T, Jacobs-Palmer E, Chang N, Much C, Turner KM, Kirby C, Rubinstein ND et al (2020) The Tug1 lncRNA locus is essential for male fertility. *Genome Biol* 21:237
- Li CJ, Hong T, Tung YT, Yen YP, Hsu HC, Lu YL, Chang M, Nie Q, Chen JA (2017) MicroRNA filters Hox temporal transcription noise to confer boundary formation in the spinal cord. *Nat Commun* 8:14685
- Li YL, Weng JC, Hsiao CC, Chou MT, Tseng CW, Hung JH (2015) PEAT: an intelligent and efficient paired-end sequencing adapter trimming algorithm. *BMC Bioinforma* 16(Suppl 1):S2
- Liaci C, Prandi L, Pavinato L, Brusco A, Maldotti M, Molineris I, Oliviero S, Merlo GR (2022) The emerging roles of long non-coding RNAs in intellectual disability and related neurodevelopmental disorders. *Int J Mol Sci* 23:6118
- Liau ES, Jin S, Chen YC, Liu WS, Calon M, Nedelec S, Nie Q, Chen JA (2023) Single-cell transcriptomic analysis reveals diversity within mammalian spinal motor neurons. *Nat Commun* 14:46
- Liau ES, Yen YP, Chen JA (2018) Visualization of motor axon navigation and quantification of axon arborization in mouse embryos using light sheet fluorescence microscopy. *J Vis Exp* 11:57546
- Lin JH, Saito T, Anderson DJ, Lance-Jones C, Jessell TM, Arber S (1998) Functionally related motor neuron pool and muscle sensory afferent subtypes defined by coordinate ETS gene expression. *Cell* 95:393–407
- Lin MF, Jungreis I, Kellis M (2011) PhyloCSF: a comparative genomics method to distinguish protein coding and non-coding regions. *Bioinformatics* 27:i275–i282
- Liu T, Wu J, Wu Y, Hu W, Fang Z, Wang Z, Jiang C, Li S (2022) LncPep: a resource of translational evidences for lncRNAs. *Front Cell Dev Biol* 10:795084
- Livet J, Sigrist M, Stroebel S, De Paola V, Price SR, Henderson CE, Jessell TM, Arber S (2002) ETS gene Pea3 controls the central position and terminal arborization of specific motor neuron pools. *Neuron* 35:877–892
- Loedige I, Baranovskii A, Mendonsa S, Dantsuji S, Popitsch N, Breimann L, Zerna N, Cherepanov V, Milek M, Ameres S et al (2023) mRNA stability and m(6)A are major determinants of subcellular mRNA localization in neurons. *Mol Cell* 83:2709–2725.e2710

- Magny EG, Pueyo JI, Pearl FM, Cespedes MA, Niven JE, Bishop SA, Couso JP (2013) Conserved regulation of cardiac calcium uptake by peptides encoded in small open reading frames. *Science* 341:1116–1120
- Makarewich CA (2020) The hidden world of membrane microproteins. *Exp Cell Res* 388:111853
- Makarewich CA, Olson EN (2017) Mining for micropeptides. *Trends Cell Biol* 27:685–696
- Matsumoto A, Pasut A, Matsumoto M, Yamashita R, Fung J, Monteleone E, Saghatelian A, Nakayama KI, Clohessy JG, Pandolfi PP (2017) mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide. *Nature* 541:228–232
- Mattick JS, Amaral PP, Carninci P, Carpenter S, Chang HY, Chen LL, Chen R, Dean C, Dinger ME, Fitzgerald KA et al (2023) Long non-coding RNAs: definitions, functions, challenges and recommendations. *Nat Rev Mol Cell Biol* 24:430–447
- Maury Y, Come J, Piskowski RA, Salah-Mohellibi N, Chevaleyre V, Peschanski M, Martinat C, Nedelec S (2015) Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes. *Nat Biotechnol* 33:89–96
- Michel AM, Fox G, M Kiran A, De Bo C, O'Connor PB, Heaphy SM, Mullan JP, Donohue CA, Higgins DG, Baranov PV (2014) GWIPS-viz: development of a ribo-seq genome browser. *Nucleic Acids Res* 42:D859–D864
- Miller A, Dasen JS (2024) Establishing and maintaining Hox profiles during spinal cord development. *Semin Cell Dev Biol* 152–153:44–57
- Miller B, Kim SJ, Mehta HH, Cao K, Kumagai H, Thumaty N, Leelaprachakul N, Braniff RG, Jiao H, Vaughan J et al (2023) Mitochondrial DNA variation in Alzheimer's disease reveals a unique microprotein called SHMOOSE. *Mol Psychiatry* 28:1813–1826
- Nassar LR, Barber GP, Benet-Pages A, Casper J, Clawson H, Diekhans M, Fischer C, Gonzalez JN, Hinrichs AS, Lee BT et al (2023) The UCSC Genome Browser database: 2023 update. *Nucleic Acids Res* 51:D1188–D1195
- Patel HP, Brouwer I, Lenstra TL (2021) Optimized protocol for single-molecule RNA FISH to visualize gene expression in *S. cerevisiae*. *STAR Protoc* 2:100647
- Patraquim P, Magny EG, Pueyo JI, Platero AI, Couso JP (2022) Translation and natural selection of micropeptides from long non-canonical RNAs. *Nat Commun* 13:6515
- Peljto M, Dasen JS, Mazzoni EO, Jessell TM, Wichterle H (2010) Functional diversity of ESC-derived motor neuron subtypes revealed through intraspinal transplantation. *Cell Stem Cell* 7:355–366
- Pueyo JI, Magny EG, Sampson CJ, Amin U, Evans IR, Bishop SA, Couso JP (2016) Hemotin, a regulator of phagocytosis encoded by a small ORF and conserved across metazoans. *PLoS Biol* 14:e1002395
- Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F (2013) Genome engineering using the CRISPR-Cas9 system. *Nat Protoc* 8:2281–2308
- Saghatelian A, Couso JP (2015) Discovery and characterization of smORF-encoded bioactive polypeptides. *Nat Chem Biol* 11:909–916
- Salvatori B, Biscarini S, Morlando M (2020) Non-coding RNAs in nervous system development and disease. *Front Cell Dev Biol* 8:273
- Shin MM, Catela C, Dasen J (2020) Intrinsic control of neuronal diversity and synaptic specificity in a proprioceptive circuit. *eLife* 9:e56374
- Sockanathan S, Jessell TM (1998) Motor neuron-derived retinoid signaling specifies the subtype identity of spinal motor neurons. *Cell* 94:503–514
- Srinivas T, Mathias C, Oliveira-Mateos C, Guil S (2023) Roles of lncRNAs in brain development and pathogenesis: emerging therapeutic opportunities. *Mol Ther* 31:1550–1561
- Stifani N (2014) Motor neurons and the generation of spinal motor neuron diversity. *Front Cell Neurosci* 8:293
- Teufel F, Almagro Armenteros JJ, Johansen AR, Gislason MH, Pihl SI, Tsigirgos KD, Winther O, Brunak S, von Heijne G, Nielsen H (2022) SignalP 6.0 predicts all five types of signal peptides using protein language models. *Nat Biotechnol* 40:1023–1025
- Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, Pachter L (2010) Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nat Biotechnol* 28:511–515
- Tung YT, Lu YL, Peng KC, Yen YP, Chang M, Li J, Jung H, Thams S, Huang YP, Hung JH et al (2015) Mir-17 approximately 92 governs motor neuron subtype survival by mediating nuclear PTEN. *Cell Rep* 11:1305–1318
- Tung YT, Peng KC, Chen YC, Yen YP, Chang M, Thams S, Chen JA (2019) Mir-17 approximately 92 Confers motor neuron subtype differential resistance to ALS-associated degeneration. *Cell Stem Cell* 25:193–209.e197
- Ulitsky I (2016) Evolution to the rescue: using comparative genomics to understand long non-coding RNAs. *Nat Rev Genet* 17:601–614
- Varadi M, Bertoni D, Magana P, Paramval U, Pidruchna I, Radhakrishnan M, Tsenkov M, Nair S, Mirdita M, Yeo J et al (2024) AlphaFold Protein Structure Database in 2024: providing structure coverage for over 214 million protein sequences. *Nucleic Acids Res* 52:D368–D375
- Vrieseling E, Arber S (2006) Target-induced transcriptional control of dendritic patterning and connectivity in motor neurons by the ETS gene *Pea3*. *Cell* 127:1439–1452
- Wang L, Park HJ, Dasari S, Wang S, Kocher JP, Li W (2013) CPAT: coding-potential assessment tool using an alignment-free logistic regression model. *Nucleic Acids Res* 41:e74
- Wichterle H, Lieberam I, Porter JA, Jessell TM (2002) Directed differentiation of embryonic stem cells into motor neurons. *Cell* 110:385–397
- Wichterle H, Peljto M, Nedelec S (2009) Xenotransplantation of embryonic stem cell-derived motor neurons into the developing chick spinal cord. *Methods Mol Biol* 482:171–183
- Wright BW, Yi Z, Weissman JS, Chen J (2022) The dark proteome: translation from noncanonical open reading frames. *Trends Cell Biol* 32:243–258
- Xiao W, Halabi R, Lin CH, Nazim M, Yeom KH, Black DL (2024) The lncRNA *Malat1* is trafficked to the cytoplasm as a localized mRNA encoding a small peptide in neurons. *Genes Dev* 38:294–307
- Yeasmin F, Yada T, Akimitsu N (2018) Micropeptides encoded in transcripts previously identified as long noncoding RNAs: a new chapter in transcriptomics and proteomics. *Front Genet* 9:144
- Yen YP, Hsieh WF, Tsai YY, Lu YL, Liao ES, Hsu HC, Chen YC, Liu TC, Chang M, Li J et al (2018) *Dlk1-Dio3* locus-derived lncRNAs perpetuate postmitotic motor neuron cell fate and subtype identity. *eLife* 7:e38080
- Zhang C, Zhou B, Gu F, Liu H, Wu H, Yao F, Zheng H, Fu H, Chong W, Cai S et al (2022) Micropeptide PACMP inhibition elicits synthetic lethal effects by decreasing CtIP and poly(ADP-ribosylation). *Mol Cell* 82:1297–1312.e1298

Acknowledgements

The authors thank past and present members of the JAC lab for their valuable comments, support, and proofreading. In particular, we appreciate Dr. Ho-Chiang Hsu for his instrumental role in initiating this project, Dr. Ee Shan Liao for acquiring axon arborization in E12.5 mouse embryos, Dr. Ji-Dung Luo for his analysis of publicly available single-cell RNA-seq data, Yi-Ching Su for mouse behavior tests, Gitartha Das for examining the MMC populations, and Chuan-Che Wu for analyzing neurite complexity. The Transgenics Core Facility of the Institute of Molecular Biology (IMB) at Academia Sinica generated the *Sertm2* KO and *Sertm2-Flag* KI mice. The authors acknowledge the excellent technical assistance from the FACS, Genomics, Bioinformatics, and Imaging core facilities in IMB. We also appreciate the National RNAi Core Facility at Academia Sinica for providing technical support for lentivirus vector packaging and Dr. John O'Brien for reviewing the manuscript. The human MNX1-tdTomato (MNX1-tdT) iPSC line was a kind gift from Prof. Hynek Wichterle

(University of Columbia). We also thank Prof. Jui-Hung Hung (National Yang Ming Chiao Tung University) and his group for analyzing the human ESC-MNs RNA-seq dataset. F-YH is supported by a National Science and Technology Council (NSTC) research fellowship, and Y-PY is supported by a NHRI postdoctoral fellowship (NHRI-EX113-11330NI). This work is funded by the National Health Research Institutes (NHRI-EX113-11330NI), Academia Sinica (AS-GCP-113-L02 & AS-BRPT-113-01), and the National Science and Technology Council (113-2326-B-001-001).

Author contributions

Fang-Yu Hsu: Conceptualization; Formal analysis; Investigation; Visualization; Methodology; Writing—original draft; Writing—review and editing. **Ya-Ping Yen:** Methodology. **Hung-Chi Fan:** Methodology. **Mien Chang:** Methodology. **Jun-An Chen:** Conceptualization; Formal analysis; Supervision; Funding acquisition; Investigation; Methodology; Writing—original draft; Writing—review and editing.

Source data underlying figure panels in this paper may have individual authorship assigned. Where available, figure panel/source data authorship is listed in the following database record: [biostudies:S-SCDT-10_1038-S44319-025-00400-0](https://www.ebi.ac.uk/biostudies/studies/S-SCDT-10_1038-S44319-025-00400-0).

Disclosure and competing interests statement

The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. Creative Commons Public Domain Dedication waiver <http://creativecommons.org/publicdomain/zero/1.0/> applies to the data associated with this article, unless otherwise stated in a credit line to the data, but does not extend to the graphical or creative elements of illustrations, charts, or figures. This waiver removes legal barriers to the re-use and mining of research data. According to standard scholarly practice, it is recommended to provide appropriate citation and attribution whenever technically possible.


© The Author(s) 2025

Expanded View Figures


Figure EV1. Features and expression of *A730046J19Rik* in the MMC and LMC of the brachial spinal cord, along with protein-coding potential and peptide validation of human *SERTM2*.

(Related to Fig. 1). (A) Multiple sequence alignments of *A730046J19Rik* reveal high conservation across four vertebrate species. The 20-way E1 track represents conserved elements among 17 primates and three other mammals. The conservation tracks were sourced from the UCSC Genome Browser. (B) UMAP visualization displaying *A730046J19Rik*, *Nr2f2*, *Satb2*, and *Bcl11b* expression in MMC MN subtypes. The dataset is derived from Liao et al, 2023. (C) RNAscope-based ISH of *A730046J19Rik*, *Satb2*, and *Nr2f2* in the E13.5 B6 brachial spinal cord. Dashed lines outline the spinal cord boundary. Scale bar, 20 μ m. (D) Scatter plots depicting correlations of gene expression in brachial LMC neurons, with the Pearson correlation coefficient indicated above each plot. (E) Mass spectrometry identified one unique peptide specific to human *SERTM2* in human tissue. The data was downloaded from Liu et al, 2022 (LncPep). (F) Protein-coding potential of human *SERTM2*, as predicted by the PhyloCSF database.


A




B




C




D




E



F





◀ Figure EV2. Investigation of coding potential and functional analysis of mouse *Sertm2*.

(Related to Figs. 2 and 3). (A) Protein-coding potential of the indicated lncRNAs, as determined in CPAT (Wang et al, 2013). Scatter plot showing the evidence-supported lncRNA-derived micropeptides (blue), lncRNAs with low coding potential (gray), and *A730046J19Rik* (red). (B) Ribosome footprint and mRNA fragment densities for *A730046J19Rik* transcripts, as provided by the GWIPS-viz browser. (C and D) Protein distribution and structure, as predicted by Phobius (C) and AlphaFold (D), respectively. (E) Design of two epitopes for *Sertm2*-targeting antibodies. (F) Validation of CRISPR/Cas9-mediated *Sertm2*-Flag KI mice by Sanger sequencing. (G) Genotyping of *Sertm2*-Flag KI mice. (H) The UniProt database identifies a glycosylation site on the N-terminal region of *Sertm2*, represented by a pink hexagon. The pink rectangle indicates the transmembrane domain within *Sertm2*. (I) *Sertm2* undergoes extensive N-glycosylation, as demonstrated by PNGase F treatment, which shifts its SDS-PAGE migration from 15–25 kDa to approximately 15 kDa. *Sertm2*-Flag from in vitro overexpression in HEK293T cells (left) and *Sertm2*-Flag KI from endogenous expression in the spinal cord (right), with both representing evidence of post-translational modifications (PTMs) of the *Sertm2* protein. Flag indicates *Sertm2* protein, and *Gapdh* serves as a loading control. (J) RNAscope-based ISH reveals the distribution of *Sertm2* in the axon during ESC-MNs. Motor axons are identified by endogenous *Mnx1::GFP*, while nuclei are highlighted by DAPI staining. White arrows show the localization of *Sertm2* within motor axons. Scale bar: 5 μ m.




Figure EV3. Analysis of *Sertm2* depletion effects on neighboring gene expression and the MMC population in the spinal cord.

(Related to Fig. 4). (A) Accurate CRISPR/Cas9 genome editing of the *Sertm2* locus in ESCs, as confirmed by Sanger sequencing. The design of sgRNAs is highlighted in blue. (B) Genotyping of the *Sertm2* knockout cell and mouse lines. (C) Graphical representation of the mouse *Sertm2* locus and its neighboring genes, *Dcx* and *Alg13* (mm10). (D) Depletion of *Sertm2* does not influence gene expression *in cis*. Data from $n = 3$ –4 independent experiments; unpaired two-tailed *t* test. *P* values for *Dcx* and *Alg13* (Ctrl vs. KO) were 0.57 and 0.57. (E) Immunodetection of Olig2, Mnx1::GFP, and Isl1/2 in E13.5 brachial spinal cord of Ctrl and KO mice. Dashed lines outline the spinal cord. Scale bar: 50 µm. (F) Immunostaining of the MMC subtype markers Bcl11b, Satb2, and Nr2f2 in E13.5 brachial spinal cord. Dashed lines outline the spinal cord boundary, and dashed circles demarcate MMC MNs. Scale bar: 50 µm. (G) Mediolateral (M–L) density plot of the Satb2⁺ and Nr2f2⁺ subtypes in the E13.5 brachial spinal cord of Ctrl and *Sertm2* mutant mice (KO) in (F). Data from $n = 4$ independent biological samples.





Figure EV4. Analysis of motor behavior in age-matched Ctrl and *Sertm2* mutant mice.

(Related to Fig. 5). (A) Time to transverse the beam (left) and the number of foot slips (right) on a 15-mm beam for Ctrl and *Sertm2* mutant (KO) mice. Data represent mean \pm SD from $n = 4$ –5 independent biological samples; unpaired two-tailed t test. $P = 0.16$ (Latency to transverse) and $P = 0.01$ (number of slips off) for Ctrl vs. KO. (B) Postnatal day (P) 90 and P120 Ctrl and KO mice were subjected to an accelerating rotarod test to measure motor performance. Latency to fall is shown. Data represent mean \pm SD from $n = 5$ –6 independent biological samples; unpaired two-tailed t test. P values for P90 and P120 (Ctrl vs. KO) were 0.02 and 0.02. (C) Motor strength was assayed according to grip strength of P90 and P120 Ctrl and KO mice. Grip strength measured in grams is displayed. Data represent mean \pm SD from $n = 6$ –7 independent biological samples; unpaired two-tailed t test. P values for P90 and P120 (Ctrl vs. KO) were 0.60 and 0.01.



◀ **Figure EV5. Verification of *Sertm2*-FS ESC lines and characterization of *SERTM2* in a human context, and verification of *SERTM2* knockout in a human iPSC line.**

(Related to Figs. 6, 7). (A) Sanger sequencing confirmed the frameshift mutation in mouse *Sertm2*-FS ESCs. (B) The PCA plot of RNA-seq data from human ESC-derived MNs (MN*X1::GFP*). Samples represent specific time points during MN differentiation: Day 8 ($n = 2$), Day 16 ($n = 3$), and Day 31 ($n = 2$). (C) GO analysis was performed for the differentially expressed genes (DEGs) associated across stages of MN differentiation. The criteria for identifying DEGs are as follows: \log_2 fold change ≥ 1 and a false-discovery rate (FDR) < 0.05 . (D) Sanger sequencing of the CRISPR/Cas9-mediated human *SERTM2* knockout human iPSC line (MN*X1*-tdT). The design of sgRNAs is highlighted in blue. (E) Genotyping of the human *SERTM2* KO line was performed using three distinct primer sets, as illustrated in Fig. 7F.